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1. The epidermal growth factor receptor pathway 
 
 The growth and proliferation of mammalian cells is a tightly regulated 
process that is modulated by stimuli from their environment. Epidermal growth 
factor (EGF)-related peptides represent a class of molecules that can trigger cell 
proliferation, and several other cellular processes such as differentiation, 
migration, and survival. Binding of EGF-like peptides to the epidermal growth 
factor receptor (EGFR) at the cell surface leads to a cascade of intracellular 
reactions that transduce signals to the nucleus, resulting in particular gene 
expression patterns. In various tumour types the regulation of EGFR activity is 
altered, due to increased or aberrant expression of the receptor or its ligands. 
EGFR deregulation contributes to many aspects of carcinogenesis. Several 
strategies have been developed that specifically target the EGFR and inhibit its 
activity in tumour cells. In particular, small-molecule EGFR tyrosine kinase 
inhibitors and antagonistic EGFR-specific monoclonal antibodies represent two 
promising classes of anti-cancer agents. 
 
Figure 1.  ErbB receptors and their ligands. Schematic protein stuctures of the four ErbB 
receptors localised on the cell membrane. On top are the ligands indicated that bind to the 
receptors. Note that no ligands have been identified that bind ErbB2, and that ErbB3 lacks a 

































1.1 Regulated activation of EGFR involves a network of receptors and 
ligands 
  EGFR, also referred to as ErbB1 or HER1, is a 170-kDa, transmembrane 
protein, consisting of an extracellular ligand-binding domain, a short 
transmembrane region and an intracellular domain containing protein tyrosine 
kinase activity. Three other ErbB proteins that are structurally and functionally 
related to EGFR have been identified: ErbB2/HER2/Neu, ErbB3/HER3 and 
ErbB4/HER4. Together, the ErbB receptors belong to the class I of receptor 
tyrosine kinases (RTKs; Figure 1). ErbB receptors exist as inactive monomers in 
the plasma membrane, and dimerise upon ligand binding, either as 
homodimers or heterodimers. A number of EGF-related peptides specifically 
bind to the ErbB1, -3, and -4 receptors, whereas no ligand for ErbB2 has been 
identified so far (Figure 1). However, ErbB2 is the preferred heterodimerisation 
partner of all other ErbB proteins 1-3, suggesting that ErbB2 principally functions 
as co-receptor. In addition, heterodimers containing ErbB2 are more stable and 
transduce signals that are more potent than other receptor dimers 4-6. Each 
ligand has specific binding properties, resulting in the formation of particular 
dimer combinations 7. However, in tumour cells in which ErbB2 is overexpressed, 
heterodimerisation with ErbB2 leads to receptor activation by a broader panel of 
ligands 8. In addition, biochemical properties of the ligand-receptor interaction 
determine the signal strength and duration, as well as the fate of the receptor, 
which is either degradation in lysosomes or recycling. For instance, EGF binding 
targets the receptor primarily to the lysosomes (Figure 2), whereas the receptor 
is recycled to the cell membrane when TGFα is bound as ligand 3,9. Thus, ligand 
diversity and specificity, as well as the variety of ErbB dimer-combinations and 
properties, regulate ErbB signalling at the input level. 
 
Figure 2.  EGF induces internalisation of EGFR. EGFR localization in H460 lung cancer cells 
was visualized with immunofluorescence. Cells were either untreated (UT, left panel) or 
stimulated with EGF for 10 minutes (EGF, right panel). 




1.2 EGFR activates various intracellular signalling pathways 
 Ligand binding drives dimerisation, intracellular kinase activation, and 
subsequent trans-autophosphorylation of specific tyrosine residues located in 
the C-terminal region of the ErbB proteins. ErbB3 lacks a functional kinase 
domain 10, and therefore can only be phosphorylated when dimerised with one 
of the other ErbB receptors. The phospho-tyrosines then serve as docking sites 
for adapter molecules such as SHC and Grb2, kinases as PI3K and Src, or negative 
regulators of receptor activity, like the tyrosine phosphatases SHP1 and 2 11. 
Each ErbB receptor displays a distinct pattern of autophosphorylation sites that 
bind different effector proteins, although considerable redundancy has been 
reported 12. The ligand identity as well as the dimer partner, determines which 
tyrosines are phosphorylated, and hence which proteins are recruited 6. 
Primarily, the mitogen activated protein kinase (MAPK) pathways are activated 
by all ErbB family members 13 (Figure 3). In contrast, ErbB3 most efficiently 
activates PI3K, as this receptor harbours six tyrosine residues that can recruit the 
p85 subunit of PI3K when phosphorylated 14. PI3K does not directly bind to 
EGFR, although the PI3K pathway can be activated by EGFR via effector 
molecules such as Grb2 15. Signal transducers and activators of transcription 
(STAT) family members are usually recruited to phospho-tyrosine sites of 
cytokine receptors, activated by JAK kinases, and translocated to the nucleus 
where they function as transcription factors 16. In contrast to JAK-mediated STAT 
activation by cytokine receptors, STAT proteins are constitutively associated 
with the inactive EGFR and are activated upon ligand stimulation independently 
from JAK kinase activity 17. The Src family of kinases is another class of 
downstream substrates of EGFR and is thought to contribute to the activation of 
numerous downstream molecules, including Ras and PI3K 18. Conversely, Src has 
been demonstrated to phosphorylate EGFR on Tyr845 18, although the 
significance of Src-mediated EGFR phosphorylation is not well understood. In 
addition, phospho-lipase Cγ (PLCγ) specifically binds and is activated by EGFR 19, 
which results in the activation of the protein kinase C (PKC) pathway (Figure 3). 
Finally, Eps15 and Cbl are specific substrates of EGFR 20,21 that have functions in 
receptor downregulation 22,23. 
 Ultimately, the kinase signalling pathways connect EGFR to transcription 





In addition to activation of gene expression, the EGFR pathway directly 
interferes with cellular processes as protein synthesis, cell survival, and cell 
motility 24-26. 
 Alternative to the activation of signalling cascades, the EGF receptor may 
directly function as a transcription factor in the nucleus 27. As the EGFR lacks a 
DNA-binding domain, EGFR-mediated transcriptional activity requires the (co) 
factor STAT3 28. 
 
Figure 3.  The EGFR signalling pathway. Activation of the EGFR induces downstream activation 
of several intracellular signalling pathways. The pathways ultimately converge in the nucleus, 
where gene transcription is activated and subsequently cellular responses are initiated. See the 































1.3 Activation of the EGFR pathway can lead to a range of responses 
 The EGFR pathway controls distinct biological processes and the actual 
physiological response depends on the particular ligand, the ErbB dimer and the 
downstream signalling pathways activated 29,30, as well as the cellular context 13. 
EGFR activity is critically involved in embryonic development 31. 
Experiments with genetically modified mice have shown the requirement for 
the EGF receptor and the other ErbB family members in development, as null 
mutations in any of the ErbB receptors are lethal 32-37. More specific analysis of 
embryos lacking the EGFR gene, revealed that EGFR is involved in organogenesis 
of many meso- and ectodermal derived organs, including brain, heart and lung 
32-34,38. In addition to embryogenesis, ErbB receptors have roles in the adult 
organism, in particular in the development of the mammary gland 39. 
 
1.4 Trans-activation of EGFR 
 It has been recently recognised that, in addition to EGF-related peptides, 
other stimuli that do not directly bind the receptor, such as hormones, 
lymphokines, and stress factors, can activate EGFR 40. From experiments using 
dominant-negative EGFR mutants and specific kinase inhibitors, it has become 
clear that this trans-activation of EGFR is essential for several, mainly mitogenic, 
responses induced by various stimuli 40. In contrast to the classical ligand-
induced activation and autophosphorylation of EGFR, trans-activation of the 
receptor is generally mediated by other protein kinases. Agonists of a range of 
G-protein coupled receptors (GPCR), including thrombin, lysophosphatic acid 
(LPA), and endothelin-1 have been demonstrated to induce mitogenic 
responses via EGFR 41. Trans-activation of EGFR by GPCRs is thought to be 
mainly mediated via c-Src tyrosine kinases 42, although GPCRs have also been 
demonstrated to activate matrix metalloproteinases involved in the cleavage of 
the EGFR-ligand proHB-EGF, thereby stimulating EGFR 43. Other stimuli that 
trans-activate EGFR include cytokines, via activation of the tyrosine kinase JAK2 
44; cell adhesion through aggregation of integrin receptors 45,46; membrane 
depolarisation, involving c-Src activation 42; stress-stimuli such as heat-shock 47, 
hyperosmotic conditions 48 or UV-irradiation 49; and insulin-like growth factor 






Table 1.  EGFR expression in different tumor types and the frequency (%) of studies 
showing an association between EGFR expression and overall survival. 
 
1.5 Increased and aberrant EGFR expression is associated with 
oncogenesis 
 Accumulation of genetic alterations or changes in the expression of 
genes involved in growth, survival and DNA repair, contribute to the 
development of cancer 71. In this regard, high expression of EGFR is frequent in 
many types of cancer, including tumours of the aerodigestive tract, breast, ovary 
and brain (Table 1). However, the expression levels between and within tumour 
types demonstrate considerable variation. Several explanations for the high 
variability have been put forward, including differences in the methods used for 
the measurement of EGFR expression, different detection thresholds, and 
heterogeneity of EGFR expression within tumours (reviewed in 51). A review of 
the literature by Nicholson and colleagues revealed that EGFR expression is a 
strong prognostic factor in tumours of the head and neck, ovary, cervix, bladder, 
and esophagus 52. In contrast, it has only a modest or poor prognostic 
significance in gastric, breast, endometrial, colorectal and non-small cell lung 
(NSCL) carcinomas 52. The true prognostic significance of EGFR could have been 
underestimated, since there was substantial diversity between the studied 
patient populations, in addition to the above-mentioned variability between 
detection methods used in the different studies. Nevertheless, several recent 
studies, including a meta-analysis considering 2185 patients, confirmed that 
Tumor type 
Proportion of tumors 
expressing EGFR (%)  
% of studies showing an association between EGFR 
expression and overall survival 
Bladder 72 51 63 (n=11) 52 
Breast 14–91 51 55 (n=11) 52 
Cervical 33-72 53-57 67 (n=6) 53,55-59 
Colorectal 25–77 51 67 (n=3) 52 
Glioma 40–63 51 n.e. 
Head and neck 43–100 51 82 (n=11) 52 
NSCLC 32–84 51 10 (n=10) 52 
Ovarian 35–70 51 67 (n=9) 52 
Pancreatic 30–95 51 n.e. 
Renal 50–93 51 n.e. 
Oesophageal 39-71 60-62 69 (n=13) 52 
Gastric 2-34 63-65 50 (n=6) 52 




EGFR overexpression or high gene copy number were not significant prognostic 
factors for the overall survival of NSCLC patients 72,73. 
Importantly, many tumours co-express EGFR and its ligands, particularly 
TGFα, which correlates with poor patient outcome 12,74 and points to autocrine 
signalling as an important force for EGFR-driven tumor growth. In addition, over-
expression of other ErbB members, in particular ErbB2, and transactivation by 
heterologous signalling networks can result in increased EGFR activity. 
Alternative to increased expression, a significant proportion of tumours 
contain a mutated EGFR gene, which most commonly translates in constitutively 
active or hyperactive forms of the receptor. A high percentage of gliomas (57-
86%) express a truncated EGFR that lacks 267 amino acids from its extracellular 
domain (EGFRvIII), due to gene rearrangements that are often associated with 
gene amplification 75,76. Although two immunohistochemical reports suggest 
that the EGFRvIII mutation occurs in several other tumour types including non-
small cell lung cancer (NSCLC) 75,77, detailed mutational studies recently revealed 
that such mutations are rare or absent in NSCLC 78-80. In contrast to the large 
deletions detected mainly in gliomas, somatic EGFR mutations were identified in 
the kinase domain of the receptor in a fraction of NSCLCs 78-80. Several different 
point mutations and small deletions were identified in exons 18 to 21 of the 
EGFR gene, encoding the kinase domain. These mutations are thought to 
translate in a receptor that is more potent in transducing growth and survival 
signals 79,81. Importantly, several studies indicate that the presence of EGFR 
kinase domain mutations strongly correlates with a dramatic clinical response to 
EGFR tyrosine kinase inhibitors (TKIs) in NSCLC patients 78-80. In addition to 
NSCLCs, EGFR kinase domain mutations have been identified at very low 
frequency in squamous cell carcinoma of the head and neck and colorectal 
tumours 82,83.  
   
Altogether, the observations that aberrant EGFR activity, due to EGFR 
overexpression or mutations, is implicated in oncogenesis point to EGFR as a 





2.  Inhibition of the epidermal growth factor receptor as 
anticancer therapy 
 
2.1 The EGFR as target for anticancer therapeutics 
It has become clear that the EGFR pathway has a role in the development 
and progression of cancer, since increased or aberrant expression of the 
receptor and/or its ligands is frequent in many types of tumours and correlates 
with a more aggressive disease and poor prognosis 84,85.  
This provides a rationale for the inhibition of the EGFR as anticancer therapy 
86. Indeed, many agents have been developed that specifically target the 
receptor, ranging from toxin-conjugated anti-EGFR antibodies or ligands to 
antisense oligo-nucleotides 87,88 (Figure 4). Among these, monoclonal antibodies 
(mAbs) directed against the extracellular domain of the receptor and small-
molecule tyrosine kinase inhibitors are the most advanced EGFR-targeted 
agents in clinical development (Table 2), and will be discussed below. 
 
Table 2.  Clinical development of ErbB inhibitors. 
Agent Characteristic Target Tumor type Stage 
Gefitinib Reversible TKI EGFR NSCLC Marketed 
Erlotinib Reversible TKI EGFR NSCLC, pancreas Marketed 
Lapatinib Reversible TKI EGFR and ErbB2 Breast Phase III 




EKB-569 Irreversible TKI EGFR Colon, SCLC Phase II 
ZD-6474 TKI EGFR and VEGFR-2 NSCLC Phase II, ongoing 
AEE788 Reversible TKI 
EGFR, ErbB2, 
VEGFR-2 
NSCLC Phase II, ongoing 
BMS-599626 Reversible TKI EGFR and ErbB2 - Phase I 
Cetuximab Chimeric mAb EGFR 




ABX-EGF Human mAb EGFR Colon, renal Phase III 






















ErbB2 Breast Marketed 







Figure 4.  EGFR targeting agents and their sites of action. 
 
2.2 Preclinical studies with monoclonal antibodies 
 In the early 1980s, Mendelsohn was the first to propose the use of 
antagonistic EGFR-specific monoclonal antibodies as anticancer therapy 86,89,90. 
Mendelsohn´s group has generated two mouse mAbs directed against the EGFR 
(mAb 528 and mAb 225) with similar affinity for EGFR as EGF and TGFα. These 
antibodies compete with the natural ligands for receptor binding, thereby 
preventing receptor activation and promoting receptor internalisation 91-93. The 
antibodies inhibit the in vitro and in vivo growth of human cancer cells derived 
from breast, prostate, lung, bladder, pancreas, head and neck, and colon 
tumours 86,89,90. To prevent an immunological human anti-mouse response that 
may compromise the therapeutic efficacy of mAb 225 when repeatedly 
administered to humans, a chimeric human-mouse mAb 225 (C225 or 
cetuximab) has been developed by replacing the murine constant region of the 
immunoglobulin with a human IgG1 constant region. Cetuximab has a 10-fold 
higher affinity for EGFR than mAb 225, and is more effective at inhibiting in vivo 
tumour growth 94. In preclinical models, mAb 225 as well as cetuximab enhance 
the anti-tumour activity of chemotherapeutic agents, such as cisplatin and 





























Another promising anti-EGFR antibody is ABX-EGF (or mAb E7.6.3), which 
is a fully human IgG2 mAb with high affinity for EGFR. ABX-EGF has been shown 
to eradicate established A431 xenografts in nude mice 99. In addition to 
antibodies directed against wt-EGFR, a panel of mAbs specifically recognising 
the type III mutated receptor (EGFRvIII) has been developed 100, from which the 
murine mAb Y10 has been proved to be the most active in vitro and in vivo 101-
103. The mechanisms underlying the activity of the anti-EGFR mAbs 
225/cetuximab are the most extensively studied, and will be discussed in more 
detail below. 
 
2.3 Mechanisms of action of mAb 225/cetuximab 
 Several molecular and biological mechanisms have been implicated in 
the anti-tumour activity of mAb 225/cetuximab 86,89,90. Anti-EGFR mAbs 
specifically inhibit ligand-induced EGFR tyrosine kinase activation, proving the 
inhibition of EGFR activation as direct mechanism of action. Treatment with 
mAb 225/cetuximab results in inhibition of tumour cell growth in vitro as well as 
in vivo 91,93,94,104. 
The growth inhibition induced by anti-EGFR mAbs is often associated 
with an arrest of cells in the G1 phase of the cell cycle. This has been shown in 
non-transformed cells 91,105 and in cultured malignant cells 106-108. In vitro studies 
demonstrated that the molecular mechanism underlying this G1 phase arrest 
involves upregulation of the CDK2 inhibitor p27kip1 108-110, which was confirmed 
in vivo using mice with xenografts derived from a human bladder tumour cell 
line 111. In addition, inhibition of the Erk and Akt kinase signalling pathways, 
which lie more directly downstream of EGFR, was associated with antitumor 
activity of cetuximab in vitro and in vivo 112,113, suggesting that the inhibition of 
Erk and/or Akt may serve as surrogate markers for EGFR inhibition. In addition, 
persistent activity of the Erk and/or Akt pathways may contribute to resistance 
to cetuximab 113.  
Cytotoxity has only rarely been observed in cells treated with the anti-
EGFR mAbs. However, mAb 225 induces apoptosis (programmed cell death) in 
the DiFi colon adenocarcinoma cell line, initiated by caspase-8 and followed by 
activation of caspase-3 and –9, resulting in the death of all cells within 48 hours 




derived from head and neck, breast and vulval tumours (e.g. A431) when treated 
with cetuximab as single agent 97,113,115. In contrast, we have not observed any 
induction of apoptosis in cetuximab-treated non-small cell lung cancer cell lines 
113. Several observations in sensitive cells support the idea that Bcl-2 family 
members are involved in regulating cetuximab-induced apoptosis. First, the 
mitochondrial, anti-apoptotic protein Bcl-2 is downregulated or inactivated 
upon cetuximab-treatment 97,115, whereas the sensitive DiFi cells lack detectable 
Bcl-2 expression 116. Moreover, transfection studies in our laboratory 
demonstrate that A431 cells overexpressing exogenous Bcl-2 were protected 
from cetuximab-induced apoptosis 113. In contrast, the protein levels of the pro-
apoptotic Bcl-2 family member Bax are upregulated in several tumour cell lines 
upon cetuximab-treatment 97,116. These studies thus demonstrate that treatment 
with anti-EGFR mAbs favours pro-apoptotic mechanisms involving Bcl-2 protein 
family members, which lead only in a subset of cell lines to the activation of 
apoptosis, suggesting that the threshold to undergo apoptosis is not reached in 
most cells by the inhibition of EGFR. 
Studies with mAb 225 or cetuximab in combination with chemotherapy 
or radiotherapy demonstrated synergistic anti-tumour activity in a range of pre-
clinical models. Combination studies with mAb 225 and cisplatin or doxorubicin 
were among the first to demonstrate augmented antitumor activity in human 
breast and vulval cell xenografts 95,96. In addition, later reports demonstrated in 
vivo synergistic anti-tumour activity between mAb 225 or cetuximab and 
subtoxic doses of paclitaxel 117, topotecan 118, and gemcitabine 38. Although the 
exact mechanism for this synergism is unclear, it is known that growth factors 
can activate pro-survival signals, so inhibition of these survival signals by mAbs 
may lower the threshold to induce cell death, as discussed above. More recently, 
cetuximab has been shown to enhance the anti-tumour effect of radiation 
therapy in cultured tumour cells as well as in tumour cell xenografts 97,98,119. In 
addition to inhibition of pro-survival signalling, potential mechanisms 
contributing to the enhanced radiosensitivity are inhibition of cell proliferation, 
resulting in reduced repopulation after radiotherapy, and inhibition of the DNA-
repair machinery (reviewed in 120). Anti-EGFR mAbs have also been shown to 





other molecules involved in EGFR signalling, including anti-ErbB2 antibodies 
119,120, farnesyl-transferase inhibitors 121, and inhibitors of protein kinase A 122. 
Several mechanisms that may play a role in vivo but not in the cell culture 
setting, such as the inhibition of angiogenesis, invasion and metastasis, as well 
as the activation of immune responses, have been suggested to contribute to 
the anti-tumour activity of cetuximab. The anti-angiogenesis effect of cetuximab 
has been proposed to be the result of the reduced secretion of angiogenesis 
factors by tumour cells, including VEGF (vascular endothelial growth factor), 
bFGF (basic fibroblast growth factor) and IL-8 (interleukin 8), which has been 
correlated with a decreased amount of new blood vessels 38,111,123. Perrotte et al. 
have also demonstrated that cetuximab-treatment of mice bearing human 
bladder carcinoma xenografts, prevents metastasis to lymph nodes and lungs 
111, suggesting the reduction of tumour cell migration by cetuximab. Although 
immune responses can be mediated via the human IgG1 part of cetuximab, 
these are not essential for the anti-tumour effect of cetuximab in vivo, as a 
truncated fragment of cetuximab lacking the human IgG1 portion was still be 
able to inhibit xenograft growth, albeit less efficiently 95. Thus, several 
mechanisms contribute to the additional anti-tumour effect of cetuximab in 
vivo, including inhibition of angiogenesis and metastasis, and possibly a minor 
induction of an immune response. 
 Based on the promising preclinical data, many clinical studies have been 
performed, some of which have been completed. Cetuximab was shown to have 
clinically significant activity when given alone or in combination with irinotecan 
in patients with irinotecan-refractory metastatic colorectal cancer 124.  On the 
other hand, the addition of cetuximab to high dose radiation in patients with 
advanced squamous cell carcinoma of the head and neck demonstrated a 
statistically significant prolongation in overall survival 125. Based on the results of 
these studies, cetuximab has been registered for the treatment of irinotecan-
refractory colorectal cancer, and will be registered shortly for the treatment of 









2.4 Preclinical studies with EGFR tyrosine kinase inhibitors 
The finding that engineered mutations in the adenosine triphosphate 
(ATP)-binding site of the EGFR disable ligand-induced responses 126,127, indicated 
that this part of the receptor is essential for EGFR tyrosine kinase activity and 
downstream signalling. In order to specifically inhibit EGFR kinase activity, 
hundreds of natural and synthetic compounds were screened searching for 
molecules that compete with ATP for EGFR-binding. Many compounds of 
different chemical classes that effectively inhibit EGFR kinase activity have been 
identified, some of which are in advanced clinical development (Table 1). These 
molecules differ in their ability to bind the EGFR ATP-binding pocket -either 
reversibly or irreversibly- or in the capacity to additionally inhibit other members 
of the ErbB family of receptors 128. Among the agents that have been 
investigated in preclinical tests, gefitinib (ZD1839 or IRESSATM) and erlotinib 
(OSI-774 or TarcevaTM) have been most extensively studied 129. A review of 
preclinical studies with EGFR-TKIs is given below, while an overview of clinical 
studies with EGFR-TKIs will be given in section 3 of this chapter. 
 
 
Figure 5.  Chemical structures of the ErbB targeting agents. 
 
2.4.1 Gefitinib 
Gefitinib is an orally active, selective, and reversible EGFR-TKI that 
chemically belongs to the class of anilinoquinazolines 129 (Figure 5). Similar to 
EGFR-blocking monoclonal antibodies 86,89,90, gefitinib induces mainly cytostatic 
effects in vitro 130,131, although cytotoxic effects have been observed in a few 











several pro-apoptotic mechanisms involving Bcl-2 family members, as the pro-
apoptotic protein BAD is activated by gefitinib in breast cancer cells 50, whereas 
overexpression of the apoptosis-suppressor Bcl-2 reverts gefitinib-induced cell 
death of A431 cells 113. 
Gefitinib is active against a wide variety of tumour cell lines 113,130-135. As 
the EGFR is part of a large signalling network 13, the sensitivity of cells to 
gefitinib is likely to be affected by multiple cellular factors. EGFR expression 
levels were initially found to be unrelated to response to gefitinib, since 
xenografts expressing high, moderate, and low amounts of EGFR showed 
growth inhibition upon gefitinib treatment 130,131. Subsequent studies, however, 
showed that cell lines with high EGFR expression levels were sensitive for 
gefitinib 135. In contrast to expression levels, the activity status of EGFR 
determined by the presence of EGFR mutations and heterodimerisation with 
other ErbB family members may be a more important predictor of gefitinib 
sensitivity (reviewed in 136).  
 
Figure 6.  EGFR gene structure and localization of mutations in hotspot regions of the 
tyrosine kinase domain. 
 
In 2004, two simultaneous publications demonstrated that somatic 
mutations in the kinase domain-encoding region of the EGFR gene were closely 
associated with a dramatic response to gefitinib in NSCLC patients 78,79. So far, 
three classes of mutations have been identified: missense mutations, deletions, 
and in frame insertions (Figure 6). Functional analysis in fibroblasts transfected 
with two different mutant forms of EGFR showed that activation of mutant EGFR 
is more intense and prolonged compared with the wild-type receptor 81. 


















activate the Akt and STAT anti-apoptotic pathways, and that treatment of these 
cells with gefitinib resulted in rapid apoptotic cell death 81. 
On the other hand, cells expressing high levels of ErbB2 have also been 
shown to be particularly sensitive to gefitinib 132,134,135. At least 100-fold higher 
concentrations gefitinib are required for the direct inhibition of ErbB2 compared 
to EGFR 137, but gefitinib may indirectly inhibit ErbB2 activity by sequestering 
ErbB2 through the induction of signalling-inactive EGFR-ErbB2 heterodimers 
138,139. In addition to ErbB2, ErbB3 is implicated in gefitinib-sensitivity, as ErbB3 
couples EGFR to the PI3K/Akt pathway in gefitinib-sensitive NSCLC cell lines 140. 
It is well-established that proteins that are involved in cell cycle 
progression, in particular p27kip1 and cyclin D, play an essential role in the G1-
phase cell cycle arrest induced by gefitinib 132,141. Moreover, we and others have 
suggested that intrinsic and persistent activity of kinase pathways downstream 
of EGFR, such as the Ras/Raf/MEK/Erk and the PI3K/Akt pathways, may provide a 
mechanism of resistance to gefitinib 113,133,134,142-144. EGFR-independent activity 
of EGFR downstream pathways may be the result of activating mutations in 
downstream molecules such as k-ras and PI3K 145,146 or depletion of the tumour 
suppressor PTEN 147. Indeed, we and others have shown that mutations in k-ras 
were associated with resistance of NSCLC cells to gefitinib 148,149. In line with this, 
depletion of PTEN by siRNA resulted in EGFR-independent activity of PI3K/Akt 
signalling and resistance to gefitinib 143. Conversely, resistance to gefitinib in 
PTEN-null HER-overexpressing tumour cells can be overcome through 
restoration of PTEN function or pharmacologic modulation of constitutive 
PI3K/Akt pathway signalling 142. 
Finally, in addition to defects within the pathway, EGFR-independent 
signalling and associated resistance to gefitinib can be a result of increased 
activation of these pathways via other growth factor or hormone receptors, such 
as IGF-1R 150. 
 
Gefitinib has been combined with a variety of cytotoxic agents. Except in 
the case of gemcitabine, the combinations resulted in enhanced antitumor 
effects in cultured cells and in vivo models 130,131. In addition, gefitinib-treatment 
resulted in synergistic effects in combination with radiation 151-153. As in de case 





synergistic effects of gefitinib and chemo- or radiotherapy is thought to involve 
inhibition of EGFR-mediated survival signals, and the decrease of the apoptotic 
threshold. Moreover, it has been suggested that gefitinib directly inhibits the 
multidrug resistant pump BCRP (or ABCG2), resulting in enhanced activity of 
antitumor drugs in BCRP-expressing cells 154-158. Importantly, sequence-
dependent effects were reported in cells treated with combinations of gefitinib 
with radiation or chemotherapy (cisplatin and/or 5-FU). The best results were 
achieved when gefitinib was applied before radiation and before or during 
chemotherapeutic treatment, whereas an antagonistic effect was observed 
when gefitinib was applied after cytotoxic treatment 151. These data indicate the 
need to be cautious in the design of clinical trials using combinations of gefitinib 
and cytotoxic agents.  
A relatively new development is the preclinical evaluation of treatment 
with gefitinib combined with other novel, biological agents, such as the ErbB2 
monoclonal antibody trastuzumab (HerceptinTM) 132,159. ErbB2 is the preferred 
dimerisation partner for EGFR, and EGFR/ErbB2 dimers are thought to induce 
more potent signals than other EGFR-containing dimers 1,2. Simultaneous 
inhibition of EGFR and ErbB2 resulted in additive or synergistic effects in ErbB2-
overexpressing breast cancer cells 132,159. These preclinical data prompted a 
currently ongoing phase II trial combining trastuzumab and gefitinib in breast 
cancer patients 160. Pharmacologic modulation of constitutive Ras/Erk or 
PI3K/Akt pathway signalling in combination with gefitinib treatment also 
resulted in enhanced cytotoxic effects 142,148.  
In addition to the often limited, antiproliferative effects observed in vitro, 
several mechanisms of action that are only active in vivo, such as inhibition of 
angiogenesis and invasion and metastasis, have been attributed to gefitinib 
137,153,161-163. The anti-angiogenesis effect of gefitinib has been proposed to be 
the result of reduced secretion of pro-angiogenesis factors 161,162, while gefitinib 
can also directly inhibit the growth and cell-cell interactions of endothelial cells 
137,137,153,162. Furthermore, combination of gefitinib with cytotoxic treatment, 








 Erlotinib is an EGFR-specific quinazoline derivative (Figure 4) that inhibits 
the activity of EGFR in cell-free assays and in intact cells at nanomolar 
concentrations (IC50 values of 2 nM and 20 nM, respectively). An initial report 
showed that erlotinib induces apoptosis and growth inhibition in several 
tumour cell lines in vitro, which was associated with the induction of p27kip1 
expression and a blockade in the G1-phase of the cell cycle 164. Moreover, 
erlotinib has a substantial effect on the growth of human head- and neck-, and 
pancreatic derived-derived xenografts growing in athymic mice, which was 
associated with a decrease in phosphorylation of Erk, but not of Akt 165,166. In skin 
and derived biopsy specimens, phosphorylated forms of EGFR, Akt, and Erk were 
decreased after treatment with erlotinib 167,168. Synergistic effects were observed 
when erlotinib was combined with cisplatin, doxorubicin, gemcitabine, and 
other cytotoxic agents in preclinical models 165,169. Moreover, erlotinib 
selectively inhibited molecular effectors such as extracellular matrix 
components, metalloproteases, and serine proteases that are involved in the 
invasion of human glioblastoma cell lines expressing the EGFRvIII mutant 170. 
This mutant receptor cannot be recognized by EGFR-specific monoclonal 
antibodies as cetuximab, illustrating one of the advantages of EGFR-TKIs over 
monoclonal antibodies. Erlotinib is currently being tested in advanced clinical 
trials in various human malignancies (Table 2).  
 
2.4.3 Other small molecule EGFR-TKIs 
Many other small molecule inhibitors some of which inhibit other ErbB 
kinases in addition to EGFR have been investigated in preclinical studies. Several 
of these inhibitors are currently being tested in the clinic and will be briefly 
discussed here.  
PD-183805 and its water-soluble analogue canertinib (CI1033), are 
irreversible inhibitors of all ErbB receptors (Table 2). These agents exhibit in vitro 
and in vivo antitumor activity as single agent, and in combination with cytotoxic 
drugs in several tumour models 171-174. Synergistic apoptotic responses were 
found when cells were treated with combinations of canertinib and gemcitabine 





to other EGFR-targeted agents, and concurrent activation of the p38 stress 
pathway was reported, together contributing to the apoptotic response. 
PKI166 is a dual EGFR/ErbB2 inhibitor that induces growth inhibition in 
several tumour-derived cell lines expressing high levels of EGFR and/or ErbB2 
175, and exhibits anti-tumour activity against several human tumour models in 
mice, commonly associated with anti-angiogenesis and anti-invasion effects 176-
180. Interestingly, when compared with an EGFR-specific kinase inhibitor (CGP-
59326), PKI-166 was more efficient to inhibit the in vitro growth of tumour cells 
in the presence of EGF-related ligands 175, suggesting more pronounced anti-
tumour effects of inhibitors that target both EGFR and ErbB2 compared to EGFR-
specific agents. 
Similar results have been published with several other small-molecule 
EGFR tyrosine kinase inhibitors in preclinical studies. Of note, lapatinib 
(GW572016), a novel dual EGFR/ErbB2 kinase inhibitor that is currently being 
tested in the clinic, has been demonstrated to be active against in vitro and in 
vivo human tumour models 181,182. Finally, EKB-569 is an irreversible inhibitor of 
EGFR activity that inhibits potently the growth of cells overexpressing EGFR or 
ErbB2, but has little effect on cells with low expression levels of these receptors 
183,184. 
 
2.5 Kahalalide F 
Kahalalide F (KF) is a novel antitumor agent that was originally isolated 
from the Hawaiian marine mollusk Elysia rufescens 185,186. KF is chemically 
unrelated to the small-molecule EGFR-TKIs described above (Figure 5), but 
reports suggested that this compound inhibits EGFR and/or ErbB2 activity and 
reduces the expression of TGFα 187,188, although ectopic overexpression of ErbB2 
did not protect against KF-induced cell death 189. In addition to EGFR and ErbB2, 
lysosomes seem to be intracellular targets of KF 189,190. In this thesis, we show 
that KF-induced cytotoxicity does not involve inhibition of EGFR or ErbB2, but 
involves downregulation of ErbB3 and downstream inhibition of Akt signalling 
191. 
KF has high cytotoxic activity against cell lines and tumour specimens 
derived from various human solid tumours, including prostate, breast, non–




antitumor activity against human prostate cancer xenografts in mouse models 
193. In contrast, nontumoral cell lines were 5 to 40 times less sensitive to KF 189, 
and bone marrow progenitors were not affected when treated with 
suprapharmacological concentrations of KF 196. In a phase I clinical trial in solid 
tumours, antitumor activity was noted in patients harbouring hepatoma, 
melanoma, and breast and pancreatic carcinoma 197, and the activity of KF is 
currently being investigated in phase II clinical trials in patients with melanoma, 
hepatic carcinoma, and NSCLC 192. 
 
3. Clinical studies with EGFR tyrosine kinase inhibitors 
 
3.1 Gefitinib 
The results of three phase I studies in patients with advanced solid 
tumours have been published 198-200. Gefitinib was one of the first targeted 
agents that have been tested in the clinic and the goals were clearly different 
from trials with cytotoxic agents. Instead of the maximum tolerated dose, one 
goal was to determine the optimal biological dose. Other goals of the study 
were to establish pharmaco-kinetic and –dynamic parameters. On the other 
hand, the fact that expression of the EGFR is common in solid tumours, and the 
preclinical evidence available, suggested that gefitinib might have a broad 
antitumor activity. This led to the inclusion of multiple tumour types and no 
selection of patients based on tumour EGFR expression. Across the dose range 
tested (50-1000 mg/day), the most frequent adverse events were dose-
dependent acneiform skin rash and grade 1 or 2 diarrhea. The latter was dose 
limiting, being severe and frequent in patients that received doses over 600 
mg/day. Other toxicities that have been observed include nausea and transient 
and asymptotic transaminitis. All of these side effects were manageable and 
reversible on cessation of treatment.  
To evaluate the effect of gefitinib on EGFR-TK activity, biopsies of the 
skin, which is known to express EGFR, were obtained before and after 28 days of 
treatment. Several known, EGFR-dependent molecular markers and downstream 
effects on proliferation were evaluated. These studies showed inhibition of 
EGFR-regulated signalling in patients treated with gefitinib, consistent with the 





and the proliferation marker Ki67 and upregulation of p27kip1, phosphorylated 
STAT3, and apoptotic cells was observed after gefitinib treatment 199,201. In these 
phase I studies, some antitumor activity was observed in patients with NSCLC, 
head and neck, ovarian, colorectal, prostate and breast cancers 198-200,202. 
The promising phase I results prompted the rapid initiation of phase II 
studies in pre-treated patients with NSCLC, hormone-refractory prostate cancer, 
advanced breast cancer, advanced colorectal cancer, head and neck cancer, 
esophageal cancer, ovarian cancer and glioblastomas, amongst others. 
Currently, data are available of two large randomised phase II studies in pre-
treated NSCLC randomised patients to 250 mg or 500 mg daily dose of gefitinib, 
doses that achieved sufficient blood concentrations to inhibit EGFR activation in 
preclinical models. One study (IDEAL1) enrolled 210 patients who received one 
prior chemotherapy regimen, which included a platinum drug 203. The response 
rate was 18.5%, while approximately 40% of patients experienced symptom 
improvement. The other study (IDEAL2) enrolled 216 patients who received 2 or 
more regimens, which included a platinum drug and docetaxel. In this study, the 
response rate was 10% 204. In both studies, withdrawals and grade III-IV adverse 
events were more frequent in patients receiving the higher dose, while the 
response rate was comparable, indicating that activity is achieved at a dose of 
250 mg, and higher doses do not generate better efficacy but lead to enhanced 
toxicity 203,204. Preliminary data of phase II trials in other tumour types indicate 
that gefitinib is generally well tolerated in combination with several cytotoxic 
therapies, and promising results have been observed in a monotherapy trial in 
recurrent or metastatic head and neck cancer 205, and in patients with advanced 
breast cancer 206. 
At the same time, two very large randomised studies have been 
concluded with gefitinib and combination chemotherapy, and final results have 
been presented 207,208. In these studies (INTACT1/2), chemo-naïve patients with 
advanced NSCLC were randomised to receive chemotherapy with placebo or 2 
different doses of gefitinib (250 or 500 mg). Chemotherapy consisted of 
carboplatin/paclitaxel (INTACT2), which is standard in North America, or 
cisplatin/gemcitabine (INTACT1), which is more frequently employed in Europe. 
These studies confirmed the safety and tolerability of gefitinib, but failed to 




gefitinib, or any of the other endpoints, which included progression-free 
survival, time to worsening of symptoms, objective tumour response, and 
quality of life. Results of a phase III trial (ISEL) in which gefitinib was given as 
monotherapy to patients with advanced NSCLC have been presented recently. 
Gefitinib failed to prolong survival compared with placebo in NSCLC patients 
who had failed one or more lines of chemotherapy 209. These clinical studies 
were robust and it was concluded that these efficacy results are definitive. 
Thus, gefitinib has been registered for second and third line therapy of 
advanced NSCLC in Japan and several other countries. However, gefitinib failed 
to improve overall survival of NSCLC patients when given as second or third line 
therapy 209. Therefore, the registration of gefitinib has been pulled back in the 
US and will be never given in Europe. 
 
3.2 Erlotinib 
Erlotinib is structurally related to gefitinib and, as observed in clinical 
studies, has a very similar toxicity and safety profile, with skin rash and diarrhea 
as dose-limiting toxicities. Promising activity has been seen in phase I trials, with 
reports of some complete responses 210-212. The dose level chosen for further 
evaluation after phase I studies, is 150 mg daily, which is a dose just below the 
maximum tolerated dose of 200 mg/day. To date, the results of three 
monotherapy phase II trials have been reported. In a study with 56 NSCLC 
patients, 7 patients (11%) achieved a partial response, while 19 patients (34 %) 
had stable disease 213. The response rate in NSCLC is similar to that obtained 
with gefitinib, indicating a consistent pattern of activity of this class of agents in 
NSCLC. Promising phase II results have also been reported for advanced ovarian 
cancer, refractory head and neck cancer, and hepatocellular cancer with 
response rates of 8.8%, 13%, and 7.9% respectively and disease stabilization in 
44%, 29% and 59% of the patients 214-217. Many phase I/II studies in various 
malignant diseases are currently being carried out with erlotinib in combination 
with several chemotherapeutics and/or radiation (reviewed in 218). In these 
studies, responses have been reported for NSCLC, penile carcinoma, head and 
neck cancer and mesothelioma, while prolonged disease stabilization was 
observed in NSCLC, mesothelioma, head and neck, bladder, ovary, stomach and 





Two large international studies of erlotinib in first-line treatment of 
advanced NSCLC in combination with chemotherapy versus chemotherapy 
alone have been concluded. These studies used the same chemotherapy 
regimens used in the gefitinib phase III studies (carboplatin/paclitaxel [‘TRIBUTE’ 
study] and cisplatin/gemcitabine [‘TALENT’ study]). Analogous to the studies 
with gefitinib, erlotinib with chemotherapy did not confer a survival advantage 
over chemotherapy alone 221,222. Nonetheless, it is encouraging that in the 
‘TRIBUTE’ study never-smokers seemed to experience an improvement in 
survival 222, which will be further investigated in future trials. 
Recently, the results of a phase III trial in which erlotinib monotherapy 
was evaluated in NSCLC patients after failure of first- or second-line 
chemotherapy have been published (BR.21 trial). Compared to the placebo 
group, erlotinib treatment resulted in prolonged survival and a higher response 
rate 223. The response rate was 8.9 percent in the erlotinib group compared to 
less than 1 percent in the placebo group (P<0.001). Progression-free and overall 
survival significantly improved from 1.8 to 2.2 months and from 4.7 to 6.7 
months, respectively, in favor of erlotinib. In addition to NSCLC, erlotinib 
significantly improved survival and progression free survival in a phase III trial in 
advanced pancreatic cancer when combined with gemcitabine 224. Based on the 
results of these studies, erlotinib has been registered for second and third line 
treatment of NSCLC and will be registered for the treatment of pancreatic cancer 
in combination with gemcitabine. 
 
3.3 Determinants of sensitivity to gefitinib and erlotinib in NSCLC 
patients 
Several factors have been put forward as potential cause for the 
disappointing results of the randomised clinical studies with gefitinib. One 
factor may be the lack of patient selection, which may have diluted a possible 
beneficial effect of the addition of gefinitib to combination chemotherapy. On 
the other hand, several reports suggest that expression levels of EGFR or ErbB2 
do not correlate with response or survival in gefitinib-treated NSCLC patients 
225,226. In contrast, some clinical parameters have been associated with gefitinib 
sensitivity, including female gender, never-smoker status, adenocarcinoma 




understanding of gefitinib responsiveness, however, came with the 
identification of somatic EGFR kinase domain mutations 78-80. After the first 
excitement about retrospective reports that predicted over 80% response rate in 
EGFR mutant NSCLC patients 78-80, the enthusiasm is somewhat tempered as 
recent reports showed only a 46-60% response rates in EGFR-mutant patients 
with no benefit on overall survival 225,228. In the same reports, EGFR amplification 
has been suggested to be an effective predictor for gefitinib efficacy and 
survival in NSCLC patients.  
In line with the results with gefitinib, the presence of EGFR mutations has 
initially been associated with responsiveness to erlotinib 80. However, 
mutational analysis of tumors from the ‘TRIBUTE’ and BR.21 trials showed that 
erlotinib-treated patients with mutant EGFR had a similar overall survival 
compared to the wild-type group, although the response rate was somewhat 
higher in the EGFR mutant group 229,230. Investigators are now focusing on other 
possible markers of erlotinib efficacy, including EGFR expression, gene 
amplification, and activation of downstream molecules such as Akt. Similar to 
gefitinib, EGFR gene copy number may be an important predictor of response to 
erlotinib 230. Conversely, the presence of k-ras mutations was associated with 
poorer clinical outcomes in patients treated with erlotinib and chemotherapy 
229, indicating that k-ras mutations may predict resistance to erlotinib. Moreover, 
clinical features that were predictive for treatment efficacy include never-
smoking status, female gender, adenocarcinoma histology, and Asian ethnicity, 
similar to gefitinib 223. Moreover, the intensity of skin rash has been correlated 
with survival in a retrospective analysis 231. The impact of EGFR mutations, 
amplification, and expression levels of ErbB receptors on gefitinib and erlotinib 
sensitivity are currently the subject of intensive investigation.  
Besides the primary resistance related to the presence of k-ras mutations 
or EGFR-independent activity of Erk or Akt pathways, resistance to erlotinib or 
gefitinib eventually develops in most NSCLC patients who initially responded to 
treatment with these EGFR-TKIs. Two groups showed that acquired resistance to 
treatment with gefitinib or erlotinib was associated with a secondary point 
mutation in the EGFR tyrosine kinase domain in some cases, leading to the 
substitution of Threonine 790 to Methionine 232,233. On the other hand, two 





TKI resistance can be present at diagnosis 234,235. Interestingly, Kobayashi et al. 
showed that treatment with the irreversible EGFR-TKI CL-387,785 can overcome 
resistance of cell lines expressing the resistant EGFR mutant 236. In addition to 
CL-387,785, the broad spectrum ErbB TKIs EKB-549 and CI-1033 were identified 
in an in vitro screening to have activity against cells expressing the resistant 
mutant 237. These data thus suggest that second-generation EGFR-TKIs can be of 
importance in the treatment of NSCLC. 
 
3.4 Other small molecules 
CI-1033 is an irreversible inhibitor of all three ErbB members that function 
as tyrosine kinase (ErbB3 lacks a kinase domain). The data of several phase I 
studies testing different administration schedules have been presented. All 
schedules were generally well tolerated. Side effects include the ones observed 
with the other small molecules, with diarrhea and skin rash as dose limiting 
toxicities. In addition, some cases of thrombocytopenia and allergy have been 
reported 238. Unfortunately, no complete or partial responses are reported in 
phase I trials, although several patients achieved stable disease 239. Phase II 
studies are currently under way, including a randomized phase II trial in patients 
with advanced NSCLC, who failed prior platinum-based chemotherapy. In this 
study, patients are selected by having at least one of the four ErbB receptors 
positive by immunohistochemistry. 
Phase I studies with the dual EGFR/ErbB2 inhibitor PKI-166 have been 
recently concluded. The major toxicities were similar to gefitinib and erlotinib, 
but an apparently higher incidence of liver toxicity has been noted with this 
agent 240. Because of the liver toxicity the further development of PKI-166 has 
been discontinued. 
The first phase I/II data with the dual EGFR/ErbB2 kinase inhibitor GW-
572016 reveal that the compound is well tolerated in patients at concentrations 
up to 1250 mg per day as monotherapy, as well as in combination with 
chemotherapeutics 241-248. In addition to skin rash and diarrhea, headache was 
one of the most common adverse events. In one study, the inhibition of 
activated Akt, activated Erk and cyclin D protein was associated with tumor cell 
apoptosis and regression of metastasis, and predicted for favorable clinical 




treatment with the anti-ErbB2 antibody trastuzumab had objective responses 
245, while two gefitinib-resistant NSCLC patients achieved minor responses 244. 
These observations suggest that the dual specificity of GW-572016 may be more 
effective in some patients compared to more specific agents. Phase II trials are 
ongoing, including in patients with trastuzumab refractory metastatic breast 
cancer and metastatic colorectal cancer 241,242.  
EKB-569 is an irreversible EGFR-specific TKI, which inhibits the growth of 
tumour cell lines that overexpress EGFR or ErbB2 in vitro and in vivo 183. The 
preliminary data of three phase I studies have been presented, in which several 
treatment schedules were tested as monotherapy in patients with advanced-
stage solid tumours 249, and in combination with cytotoxic agents in patients 
with advanced pancreatic 250 and colorectal cancer 251. Again, the results showed 
mild diarrhea and skin rash as major toxicities, indicating that EKB-569 is 
generally well tolerated. 
 
In summary, the mechanism of action of the small molecule EGFR-TKIs 
involves the direct inhibition of EGFR activity and/or other ErbB members. The 
presence of mutations in the kinase domain-encoding region of the EGFR gene 
and EGFR gene amplifications have been strongly associated with sensitivity to 
EGFR-TKIs. In addition, the expression of ErbB2 or ErbB3 are markers of EGFR-TKI 
sensitivity, while expression levels of EGFR may be of importance in EGFR wild-
type cells. High expression of p-Akt, in particular in EGFR positive cells, has been 
associated with gefitinib sensitivity of NSCLC patients, whereas k-Ras mutations 
may predict for resistance to EGFR-TKIs. Effective inhibition of downstream 
Ras/Erk and PI3K/Akt kinase pathways has been linked to the antiproliferative 
and –sometimes- pro-apoptotic effects of the EGFR-TKIs. Upregulation p27kip1, 
downstream of Akt, appears to be essential for the growth delay induced by 
these agents. EGFR-TKIs have been shown to be potent inhibitors in vivo of 
tumour growth, anti-angiogenesis agents and to inhibit invasion and metastasis 






4. Outline of the thesis 
 
The Introduction (Chapter 1) describes the epidermal growth factor receptor 
(EGFR) pathway and its role in embryonic development and cancer. The 
mechanisms of EGFR activation, and the downstream molecular and cellular 
effects are discussed. An overview is given of the status of ErbB-targeted 
therapies in preclinical and clinical development. In this thesis we have 
investigated the molecular mechanisms of ErbB-targeting anti-tumour agents, 
and examined several biological markers that may predict the outcome of 
cancer patients treated with such agents. 
In Chapter 2 we have investigated the molecular and cellular mechanism 
of action of EGFR inhibitors. Regarding the promising results of early clinical 
trials with the EGFR-TKI gefitinib in NSCLC patients, we were mainly interested in 
the effects of gefitinib in NSCLC-derived cell lines, and we compared gefitinib 
with the EGFR-specific antibody cetuximab. Since we observed that persistent, 
EGFR-independent activity of the downstream PI3K/Akt and/or Ras/Erk kinase 
pathways was associated with resistance to EGFR inhibitors, we tested the 
hypothesis described in Chapter 3 that combining gefitinib with agents 
specifically inhibiting these downstream molecules may result in enhanced anti-
proliferative or cytotoxic effects.  
Chapter 4 describes the results of a clinical study of gefitinib 
monotherapy in previously treated, advanced esophageal cancer patients. 
Although the response rate was disappointing (2.8%), a considerable proportion 
of patients experienced stable disease (27.8%). We attempted to identify the 
patients that had benefit from gefitinib treatment, and for that purpose, we 
analyzed tumor material for several biological features. Although no EGFR 
mutations were detected, the patient outcome was significantly better in 
patients demonstrating high EGFR immunohistochemical expression. 
Conversely, k-ras mutations were found in two patients with progressive 
disease. In addition, squamous cell carcinoma histology or female gender 
predicted for better patient outcome. 
 In Chapter 5 we investigated the molecular mechanism of action of the 
novel, marine-derived anti-tumor agent Kahalalide F (KF). Although this 




KF-induced cytotoxicity involves downregulation of the EGFR-related receptor 
ErbB3 and downstream inhibition of Akt activity. 
Finally, the results presented in this thesis and their implications in the 
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 The epidermal growth factor receptor (EGFR) is an important novel 
target for anticancer therapy. In this study, we examined the molecular 
mechanisms that underlie the antitumor effects of the anti-EGFR monoclonal 
antibody C225 (Cetuximab) and the selective EGFR-tyrosine kinase inhibitor 
ZD1839 (‘Iressa’) in non-small cell lung cancer (NSCLC) cell lines. Cell growth, 
assessed by the MTT assay, was inhibited at low concentrations of ZD1839 and 
C225 in control A431 cells, whereas the NSCLC cell lines were comparatively 
more resistant. In A431 cells, but not in the NSCLC cells, ZD1839 treatment 
resulted in a modest increase in DNA fragmentation, the externalisation of 
phosphatidyl-serine, and the activation of caspase-3, known markers of 
apoptotic cell death. However, PARP-cleavage was not detected and caspase 
inhibition by zVAD-fmk partially reduced ZD1839-generated DNA 
fragmentation. Overexpression of the anti-apoptotic protein Bcl-2 in A431 cells 
suppressed the cytotoxity upon anti-EGFR treatment. These results thus 
demonstrate that the toxic effect of ZD1839 in A431 cells is caused by a form of 
cell death that involves a mitochondrial step and is at least in part dependent 
on caspase activation. EGFR expression levels showed no significant correlation 
with sensitivity to ZD1839 and C225. Evaluation of the MEK/Erk and PI3K/Akt 
pathways showed considerable inhibition of these pathways by ZD1839 and 
C225 in A431 cells, whereas one or both of these pathways remained active 
upon anti-EGFR treatment in NSCLC cells. In addition, treatment with specific 
inhibitors of MEK or PI3K resulted in a smaller effect on proliferation than 
simultaneous treatment with both inhibitors, while induction of apoptosis was 
observed only when both pathways were blocked. Together, these data suggest 
that persistent activity of either of these signalling pathways is involved in the 
lack of sensitivity of NSCLC cell lines to EGFR inhibitors. 





 High expression of the EGFR2 and/or its ligands is common in several 
tumor types, including head and neck cancer, breast cancer, ovary cancer, and 
NSCLC, and correlates with more aggressive disease, resistance to 
chemotherapy, and a poor prognosis 1. Moreover, in lung and other tumors 
coexpression of EGFR and its ligand TGFα is common, suggesting an important 
role for the EGFR/TGFα autocrine loop in cancer 1,2. 
EGFR is a 170 kD transmembrane protein consisting of an extracellular ligand 
binding domain, a transmembrane domain and an intracellular tyrosine kinase 
domain. Upon ligand binding, the receptor dimerizes, either as homodimer or 
as heterodimer with other members of the ErbB family of receptor tyrosine 
kinases, preferably ErbB2 (HER2), and undergoes autophosphorylation at 
specific tyrosine residues of the intracellular domain. The phosphorylated 
tyrosine residues then serve as docking sites for proteins like Grb2, Shc and PLC 
that, in turn, activate downstream signalling pathways, including the 
Ras/MEK/Erk and the PI3K/Akt pathway, that regulate transcription factors and 
other proteins involved in biological responses as proliferation, cell motility, 
angiogenesis, cell survival, and differentiation 3,4. 
 Two main strategies have been developed to target the EGFR and block 
its activation in cancer cells 5,6. Monoclonal antibodies against the extracellular 
domain of EGFR compete with ligand for receptor binding, thereby preventing 
kinase activation. An example of this is the human-mouse chimeric Mab C225 
that has a high affinity for EGFR and is currently in phase II and III clinical trials in 
head and neck cancer, colorectal cancer and other tumor types 7. Other 
promising anti-EGFR agents are EGFR-TKIs that prevent autophosphorylation of 
EGFR by physical interaction with its intracellular kinase domain. ZD1839 
(‘Iressa’) is an orally active, selective EGFR-TKI 8 that is currently in phase II-III 
clinical trials, in patients with NSCLC, among several tumor types 9-11. 
 Various preclinical studies have demonstrated antitumor effects of C225 
and ZD1839 in a variety of cell types and mouse xenografts as single agents and 
in combination with other anticancer therapies, in particular chemotherapeutic 
agents and radiation 12-15. As single agents, the EGFR antagonists induce in vitro 
growth inhibition and, in some cell lines, apoptosis 16,17. 
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 To define potential markers that could predict the outcome of anti-EGFR 
treatment, we investigated the molecular mechanisms that underlie the 
antitumor effects of the EGFR antagonists C225 and ZD1839 in NSCLC cells. We 
used a panel of four NSCLC cell lines and the highly EGFR expressing A431 cell 
line and determined in vitro cytotoxic and cytostatic effects after exposure to 
ZD1839 or C225. The EGFR inhibitors induced effective growth inhibition of 
A431 cells, while all of the NSCLC cell lines were more resistant. Cytotoxic effects 
were only observed in the A431 cell line, in which the role of apoptosis was 
further investigated. Protein expression levels of neither EGFR nor ErbB2 
correlated with sensitivity to EGFR antagonists. In addition, the activity of kinase 
pathways downstream of the EGFR via MEK/Erk and PI3K/Akt was determined 
after treatment with EGFR inhibitors, showing persistent activity of at least one 
of these pathways in the NSCLC cell lines. Treatment with a combination of 
specific chemical inhibitors targeting MEK and PI3K resulted in the induction of 
apoptosis and effective inhibition of cell growth. Together, the results indicate 
that persistent activity of the MEK/Erk and PI3K/Akt kinase pathways can 
contribute to resistance of NSCLC cells to EGFR inhibitors.  
 
Materials and Methods 
 
Chemicals 
 Anti-EGFR Mab C225 was kindly provided by Merck, Germany, at a concentration of 2.0 
mg/ml. Kinase inhibitors were provided as pure substances and diluted in DMSO. ZD1839 was a 
kind gift from AstraZeneca. U0126 and LY294002 were purchased from Cell Signalling 
Technology (Beverly, MA). The broad caspase inhibitor Carbobenzoxy-Val-Ala-Asp-fluoromethyl 
ketone (zVAD-fmk) was purchased from Enzyme Systems (Livermore, CA). The stock solution of 
cisplatin (Bristol-Meyers Squibb, Woerden, The Netherlands) was made in PBS. 
 
Cells and culture conditions 
 RPMI 1640 (containing 2 mM L-glutamine) and DMEM were used as culture media and 
were supplemented with 10 % heat-inactivated fetal calf serum (Gibco BRL, Life technology, 
Breda, The Netherlands), 50 iu/ml penicillin and 50 µg/ml streptomycin. The human NSCLC cell 
lines NCI-H460 (H460), NCI-H1703 (H1703), and A549 cells were cultured in RPMI 1640, the 
human NSCLC cell line SW1573 and the vulval squamous cell carcinoma cell line A431 were 
cultured in DMEM. Cells were grown at 37° C in a humidified atmosphere with 5 % CO2. Cells 
from exponentially growing cultures were used in all experiments. 
Effect of EGFR inhibition in NSCLC cell lines 
 
 55
Cloning, retroviral transduction, and selection of stable cell lines 
 The DNA sequence encoding Bcl-2-FLAG was amplified with PCR using the 
pEFFLAGBCL2pGKpuro vector, which was a kind gift of Dr. Strasser 18, as template. The PCR 
fragment was inserted in the retroviral vector pLNCX2 (Clontech, Palo Alto, CA) using HindIII and 
BglII restriction sites, and the products were verified by sequencing. To make stable retrovirus-
producing cells, the packaging cell line PT67 was transfected with 5-10 g cDNA, using 
Superfect reagent (Gibco BRL) according to the manufacturer’s protocol. Transfected cells were 
grown in genecitin-containing medium and resistant colonies were selected and expanded. The 
stable transfected cells were then grown in medium without genecitin for 72 h, and 
subsequently the supernatant containing the virus was harvested and filtered through a 0.45 
µm filter. After addition of hexadimethrine bromide (polybrene; Sigma, St Louis, MI) to a final 
concentration of 8 µg/ml, it was used to infect A431 cells. After 24 h, the virus-containing 
medium was removed and cells were selected in medium containing genecitin and resistant 
colonies were expanded. Expression of FLAG-Bcl-2 was confirmed by Western blotting using the 
M2 antibody that recognises the FLAG-epitope (Stratagene, La Jolla, CA). 
 
Growth inhibition assay 
 For growth inhibition assays, 1 x 104 cells were plated into flat bottom 96-well plates 
(Costar, Corning, NY). After 24 h, various concentrations of the indicated drug were added and 
the cells were incubated for an additional 72 h.  Subsequently, 10 % (v/v) of a solution of 5 
mg/ml MTT (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) was added 
to each well and incubated for 3 h at 37o C. Plates were centrifuged for 5 min at 1000 rpm and 
the medium was carefully discarded. The formed formazan crystals were dissolved in 100 µl 
dimethylsulfoxide (DMSO) and absorbance was determined at 540 nm using a Spectra 
Fluorimeter (Tecan, Salzburg, Austria). Absorbance values were expressed as the percentage of 
the untreated controls and the concentration of ZD1839 resulting in 50 % growth inhibition 
(IC50) was calculated. For C225 treatment, the percentage of maximal inhibition of growth was 
determined at a concentration of 10 µg/ml, since at higher concentrations of the antibody no 
additional growth inhibition was observed, presumably due to saturation of EGF receptors. 
  
Clonogenic assay 
 Three hundred cells/well were seeded in triplicate into six well plates. Twenty-four 
hours later, the medium was replaced by medium containing ZD1839 or C225 at the indicated 
concentrations. After 72 h, the drugs were removed and cells were washed twice with PBS and 
allowed to grow in normal medium for 7 days. Finally, cells were stained with 0.1% crystal violet 
in PBS for at least 30 min at room temperature and colonies were counted. Clonogenic survival 






Cell cycle analysis and cell death measurement 
 Cells were plated at a density of 1 x 105 cells per well in six wells plates (Costar, 
Cambridge, MA). Twenty-four hours later, the medium was replaced by medium containing the 
drug(s) as indicated. EGFR antagonists ZD1839 and C225 were used at concentrations of 1 µM 
and 5 µg/ml, respectively, and LY294002 and U0126 at a concentration of 30 µM and 10 µM, 
respectively. The broad-spectrum caspase inhibitor zVAD-fmk was added 1 h before treatment 
at a concentration of 50 µM when indicated. The cell cycle distribution was analysed of cells 
stained with propidium iodide (PI) 19, and the extent of cell death was determined by measuring 
the sub-G1 population. Apoptotic events were measured by annexin-V-FITC and 7-amino-
actinomycin D (7-AAD) double staining according to the manufacturer’s protocol (Nexins 
Research, Kattendijk, The Netherlands). All analyses were performed on a FACScalibur 
instrument using the CELLQuest or the ModFit 3.0 software packages (Becton Dickinson). 
 
Caspase-3-like enzyme activity assay 
 Caspase-3-like enzyme activity was assayed in cellular extracts using the ApoAlert 
caspase-3 kit (Clontech Laboratories Inc., Palo Alto, CA) according to the manufacturer’s 
instructions. Fluorescence was detected using a Spectra Fluorimeter equipped with a 400-nm 
excitation filter and a 505-nm emission filter (Tecan, Salzburg, Austria). Relative caspase activity 
was expressed as the level of DEVD-AFC cleavage in the treated cells compared to the level in 
the untreated controls. 
 
Detection of EGFR and ErbB2 expression by flow cytometry 
 5x105 cells were harvested using trypsin and incubated for 1 h at 4 °C with 1 µg of the 
anti-EGFR Mab C225 (Merck) or the anti-ErbB2 Ab-2 (Neomarkers, Fremont, CA). As a control for 
non-specific binding, 1 µg of protein of human IgG1 lambda (Sigma) and mouse IgG1 (DAKO, 
Santa Barbara, CA), for the EGFR and ErbB2, respectively, were used as isotype-matched non-
binding antibodies. Subsequently, cells were washed twice with ice-cold PBS containing 0.5 % 
BSA and incubated at 4° C in the dark for 1 h with fluorescein-isothiocyanate (FITC)-conjugated 
goat-anti-human or goat-anti-mouse IgG antibody, diluted 1:50 in PBS/BSA. After two washing 
steps with ice-cold PBS/BSA, cells were resuspended in 0.5 ml ice-cold PBS/BSA and analysed on 
a FACScalibur flow cytometer using CELLQuest software (Becton Dickinson, Mount View, CA). 
Relative expression levels were calculated as the ratio between the mean fluorescence intensity 
(MFI) of cells stained with the specific antibodies and the MFI of cells stained with the respective 
isotype-matched control antibody. 
 
Western blotting 
 Cell lysates were prepared in a buffer containing 20 mM HEPES/KOH (pH 7.4), 50 mM β-
glycerophosphate, 50 mM KCl, 0.2 mM EDTA, 1 % (w/v) Triton X-100 and 10 % (w/v) glycerol. A 
protease inhibitor cocktail (Roche, Almere, The Netherlands) and 1 mM NaVO3 was freshly 
added to the lysis solution before each experiment. Protein concentrations were determined 
according to Bradford 20, using the Protein Assay Dye Reagent Solution (BioRad) with bovine 
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serum albumin as a standard. Cell lysates were denatured in sodium dodecyl sulfate (SDS) and 
equal amounts of protein were electrophoresed on 7-12 % SDS-polyacrylamide gels and 
transferred to nitrocellulose membranes. Subsequently, membranes were blocked with 5 % 
non-fat dry milk for 1 h at room temperature and incubated overnight at 4° C with the 
appropriate primary antibodies. After incubation with horseradish peroxidase-conjugated goat-
anti-mouse or goat-anti-rabbit antibodies for 1 h at room temperature, detection was 
performed using the enhanced chemiluminescence (ECL) reagent (Amersham). The following 
antibodies were used: anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-Erk, anti-Erk, anti-
phospho-GSK3β anti-phospho-p90rsk (all from Cell Signaling Technology, Beverly, MA), and anti-




Differential effects of anti-EGFR agents on proliferation and survival in 
A431 and NSCLC cells 
 The growth of A431 cells is known to be potently inhibited by EGFR 
inhibitors 21-23. In this study, we have used MTT assays to determine the effect of 
ZD1839 and C225 on the growth of several NSCLC cell lines in comparison to 
the highly sensitive A431 cells. ZD1839 induced 50 % growth inhibition in 
NSCLC cell lines at concentrations that were 24 to 240 times higher than the 
IC50 for A431 cells (Table 1). At concentrations of ZD1839 greater than 1 µM, the 
antiproliferative effect of ZD1839 may be mediated by actions additional to 
inhibition of EGFR 24. Therefore, the growth inhibition induced at 1 µM ZD1839 
compared to untreated control cells is also presented in Table 1, showing a 
growth inhibition of 77 % in A431 cells at this concentration, while the growth 
inhibition ranged from not more than 20 to 30 % in most lung cancer cells to 46 
% in the A549 cell line. Similarly, C225 induced a more pronounced growth 
inhibition of A431 cells than of the NSCLC cells (Table 1). However, compared to 
ZD1839, C225 was less potent in suppressing growth of A431 cells in the MTT 
assay (Table 1).  
 In the context of a cell population, growth inhibition may result either 
from decreased cell proliferation or decreased cell survival. To distinguish 
between these possibilities, we carried out clonogenic assays on cells exposed 
to ZD1839 or C225 for a limited period of time. As the effect of ZD1839 is 
reversible upon removal 25, cells would be able to resume growth and give rise 
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to a colony unless their survival is compromised. ZD1839 did not reduce the 
clonogenic survival in any of the NSCLC cell lines, whereas treatment with 
ZD1839 resulted in a 50-60 % reduction of A431-derived colonies (Table 1). 
Similar results were obtained with C225 in this assay (Table 1). 
 
Table 1.  Comparison of protein expression levels of EGFR and ErbB2, ZD1839- and C225-
induced growth inhibition and clonogenic survival. 
 
Growth inhibition  Clonogenic survival 










































 n.d.e n.d. 




















a Protein expression levels were analysed by flow cytometry (see Materials and Methods). 
b Drug concentrations (µM) responsible for 50% growth inhibition in MTT assay at 72 h, 
calculated with data of at least three independent experiments. 
c Growth inhibition induced by ZD1839 (1 µM) or C225 (5 µg/ml) represented as % of untreated 
cells, analysed by MTT assay at 72h. Mean and s.d. are shown of at least three independent 
experiments. 
d Colony-forming units are expressed as a percentage of the respective untreated control. Mean 
and s.d. are shown of one representative experiment performed in triplicate. 
e n.d., not determined 
 
Effects of ZD1839 and C225 on cell cycle progression 
 In order to examine if the inhibitory effects observed in growth assays 
reflect a delay or arrest of cells in the G1/G0 phase, as shown previously 14,26, 
cells were treated with ZD1839 (1 µM) or C225 (5 µg/ml) for 72 h and the cell 
cycle progression was evaluated following propidium iodide staining and FACS 
analysis. An increase in the portion of cells in the G1/G0-phase of the cell cycle 
by 17-20% in A431 cells and 6-7% in A549 cells with a corresponding decrease 
in cells in S- and G2/M-phase was observed upon treatment with ZD1839 or 
C225 (Figure 1), correlating with the antiproliferative effects observed in these 
cells (see Table 1). In contrast, in H1703, SW1573, and H460 cells no change in 
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cell cycle distribution was detected upon treatment with the EGFR inhibitors 
(Figure 1), correlating with the limited antiproliferative effects observed in these 
cell lines at the concentrations used (see Table 1). 
 
 Interestingly, a significant ZD1839- and C225-dependent increase in the 
sub-G1 cell population was detected in A431 cells, but not in any of the NSCLC 
cell lines (Figure 1). Cells in sub-G1 population may represent apoptotic cells, 
suggesting that the induction of apoptosis contributes to the cytotoxic effect of 
the EGFR inhibitors in A431 cells. 
 
 
Figure 1.  Cell cycle analysis of cells treated with EGFR antagonists. A431 and NSCLC cells 
were stained with propidium iodide (PI) after 72 h exposure to ZD1839 (1 µM) or C225 (5 µg/ml) 
and analysed by flow cytometry. Percentages of the total cell population in the different phases 
of the cell cycle were determined and included. Representative results of at least three 





































































Cytotoxity of ZD1839 in A431 cells is blocked by Bcl-2 overexpression and 
is partially caspase-dependent 
 To investigate the involvement of apoptotic cell death in ZD1839-
induced cytotoxity in A431 cells, several known markers of apoptosis were 
evaluated. First, we examined the involvement of the anti-apoptotic protein Bcl-
2, which is able to stabilise the mitochondrial membrane, thereby preventing 
mitochondria-dependent caspase activation 27. It has been suggested that Bcl-2 
family members have a role in apoptosis induced by EGFR-targeted agents 16,28. 
To test the involvement of mitochondria in ZD1839-induced toxicity, we used 
retroviral transduction to generate an A431-derived cell line stably 
overexpressing Bcl-2. Overexpression of Bcl-2 prevented from the ZD1839-
induced increase of externalised PS (phosphatidyl serine; Figure 2A), a 
phospholipid that is normally confined to the inner leaflet of the plasma 
membrane and is externalised upon induction of apoptosis. To identify late 
apoptotic and necrotic cells, membrane integrity was investigated by staining 
with 7-AAD. In addition, Bcl-2 overexpression favoured clonogenic survival of 
A431 cells treated with ZD1839 or C225 (Figure 2B). Interestingly, cells 
overexpressing Bcl-2 formed colonies that were significantly larger in size than 
the control vector transduced cells (Figure 2B), further illustrating the pro-survival 
effect of Bcl-2. 
 
Figure 2.  Overexpression of Bcl-2 protects from ZD1839-induced PS externalisation and 
results in clonogenic survival of A431 cells treated with ZD1839 or C225. A431 cells stably 
transfected with an empty retroviral vector (A431-Vector) or a vector encoding Bcl-2 (A431-Bcl-
2) were treated with ZD1839 (1 µM) or C225 (5 µg/ml) for 72h. (A) The percentage of apoptotic 
cells represents the fraction of cells that were positively stained with annexin-V, measuring the 
amount of externalised PS, as analysed by flow cytometry (see also Fig. 3). (B) Clonogenic 
survival of A431-Bcl-2 cells, but not of A431-vector cells. Pictures were taken from representative 
experiments. Colony-forming units are expressed as a percentage of untreated cells and 
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Figure 3.  Partial contribution of caspase-dependent apoptosis on ZD1839-induced 
cytotoxity in A431 cells. (A) Cells treated with ZD1839 (1 µM) for 72h were double-stained with 
annexin-V/7-AAD and analysed by flow cytometry. Gate-settings distinguish between living 
(lower left), necrotic (upper left), early apoptotic (lower right) and late apoptotic (upper right) 
cells. (B) DEVD-AFC cleavage was measured in treated and untreated cells in the presence or 
absence of caspase inhibitors. A representative experiment is shown. (C) Cells were treated with 
ZD1839 (1 µM) for 72 h or cisplatin (10 µM) for 48 h in the presence or absence of zVAD-fmk. 
Mean and s.d. are shown from three experiments. (D) Western blot analysis of PARP cleavage in 
A431 cells treated with ZD1839 (1 µM) for 72 h or different concentrations of cisplatin for 48 h. 
 
As a marker for apoptotic cell death, the exposure of PS was analysed by 
staining with annexin V-FITC. Upon treatment of A431 cells with ZD1839, a 2-
fold increase of cells stained with annexin V-FITC was detected (Figure 3A), 
which is comparable to the fraction of cells in sub-G1 phase under these 
conditions. In ZD1839-treated NSCLC cells, no externalisation of PS was 
observed (data not shown), corresponding with the lack of a cytotoxic effect in 










































































caspase-3-like activity was determined by measuring the cleavage of its 
fluorescent substrate DEVD-AFC. Caspase-3-like activity increased 4.5 times in 
cells treated with ZD1839 compared to 11.7 times in cisplatin-treated cells 
(Figure 3B), indicating that caspase-3 is activated to a lesser extent by ZD1839 
than by cisplatin. As controls, ZD1839- and cisplatin-induced caspase-3-like 
activity was completely blocked when the broad-spectrum caspase inhibitor 
zVAD-fmk was added during drug exposure (Figure 3B) or when the specific 
caspase-3 inhibitor DEVD-CHO was added to the reaction mixture during the 
cleavage reaction (data not shown). Of note, zVAD-fmk decreased the 
proportion of cells with a hypodiploid DNA content induced by ZD1839, and 
completely prevented the appearance of the sub-G1 population in cisplatin-
treated cells (Figure 3C). No PARP-cleavage was detected in A431 cells treated 
with ZD1839, whereas in control cells treated with different concentrations of 
cisplatin, a dose-dependent increase in PARP-cleavage was observed (Figure 
3D). The lack of PARP-cleavage in ZD1839-treated cells could be due to the low 
amount of apoptosis that was induced, making it impossible to detect the 
cleaved fragment. In support of this, no PARP-cleavage was detected in cells 
treated with 1 µM cisplatin (Fig. 3D), a concentration that induces a sub-G1 
population (11%) that was similar to that resulting from ZD1839-treatment 
(data not shown). Taken together, these results demonstrate that the induction 
of caspase-dependent apoptosis contributes, at least in part, to the cytotoxity 
induced by ZD1839 in A431 cells. 
 
Lack of correlation between EGFR or ErbB2 expression levels and ZD1839 
and C225 toxicity in NSCLC cells 
 It is not yet known whether sensitivity to EGFR inhibitors depends on the 
amount of EGFR 23,29,30 and/or ErbB2 22,23,26 expressed by cells. The NSCLC cell 
lines used in this study expressed moderate levels of EGFR when compared to 
the control A431 cell line that expresses very high levels of EGFR (Table 1). 
Expression of ErbB2, on the other hand, was similar in all cell lines (Table 1). As 
previously reported 21-23, the highly EGFR expressing A431 cells were extremely 
sensitive to the EGFR inhibitors, but neither EGFR nor ErbB2 expression 
correlated with the growth inhibitory effect of ZD1839 or C225 within the panel 
of NSCLC cell lines.  




Figure 4.  Persistent activity of Erk or Akt in NSCLC cell lines, but not in A431 cells. (A-C) 
A431, A549, and H460 cells were serum-starved overnight and treated with ZD1839 (1 µM), 
C225 (5 µg/ml), U0126 (10 µM), or LY294002 (30 µM) for 2 h prior to exposure to 10 ng/ml EGF 
for 5 minutes. Equal amounts of protein were separated by SDS-PAGE and transferred to 
nitrocellulose membranes, which were immunostained for phosphorylated Erk and Akt. As 
control for protein loading, membranes were stripped and reprobed with antibodies 
recognising β-actin.  
 
Effects of ZD1839 and C225 on kinase signalling downstream of EGFR 
 EGFR signalling is transduced through two main kinase pathways, 
involving MEK/Erk and PI3K/Akt 31. Intrinsic activity of these pathways can 
potentially circumvent EGFR inhibition. Phosphorylation of Erk and Akt was 
analysed to determine the activation status of the two pathways upon anti-
EGFR treatment. The sensitive A431 cell line and two NSCLC cell lines (A549 and 
H460) were treated with the EGFR antagonists ZD1839 or C225, the MEK 
inhibitor U0126, or the PI3K inhibitor LY294002 prior to stimulation with EGF. 
Cell extracts were subsequently subjected to Western blot analysis. Non-
stimulated A431 control cells displayed strong bands corresponding to 
phosphorylated Erk and Akt, and stimulation with EGF resulted even in a slight 


















and Akt was abolished in ZD1839-treated A431 cells (Figure 4A, lane 3), which is 
in agreement with previous observations by others in these cells 21,23. Compared 
to ZD1839, C225 only partially reduced phosphorylation of these downstream 
molecules in A431 cells (Figure 4A, lane 4). This may explain the smaller effect of 
the anti-EGFR antibody on growth, as shown earlier in the MTT assay and 
suggests less effective EGFR kinase inhibition by C225 than by ZD1839 in A431 
cells. As expected, the MEK inhibitor (U0126) and the PI3K inhibitor (LY294002) 
specifically inhibited Erk or Akt phosphorylation, respectively (Figure 4A, lane 5 
and 6). Unlike A431 cells, phosphorylated Erk, but not Akt, was present in 
serum-deprived A549 cells (Figure 4B, lane 1), while the reverse was found in 
H460 cells, having phosphorylated Akt and non-phosphorylated Erk (Figure 4C, 
lane 1), suggesting intrinsic activity of one of the kinase pathways in these cells. 
Incubation with EGF resulted in a significant increase of phosphorylated Erk and 
Akt in both cell lines (Figure 4B and C, lane 2), demonstrating the functionality 
of the EGFR pathway in these cells. Treatment with ZD1839 or C225 resulted in 
the decrease of phosphorylation of Erk and Akt to the levels seen in the 
untreated controls, with activated Erk (in A549 cells) or Akt (in H460 cells) still 
detectable (Figure 4B and C, lanes 3 and 4). However, in both lung cancer cell 
lines, treatment with U0126 or LY294002 completely abrogated Erk or Akt 
phosphorylation, respectively (Figure 4B and C, lanes 5 and 6). 
 These results clearly indicate that the Erk or Akt kinase pathways are 
constitutively active and are not effectively blocked by EGFR antagonists in the 
NSCLC cell lines A549 and H460, respectively. 
 
Dose-dependent inhibition of EGF-induced signalling via Erk and Akt 
kinase pathways by ZD1839 
 To further substantiate the latter findings, we extended our analysis to 
other NSCLC cell lines and treated with different concentrations of ZD1839. In 
addition to Erk and Akt phosphorylation, the cell extracts were analysed for 
phosphorylation of p90rsk and GSK3β, which are downstream substrates of Erk 
and Akt, respectively 32,33. A dose-dependent decrease of Erk and Akt 
phosphorylation was observed in A431 cells, coinciding with decreased 
phosphorylation of p90rsk and GSK3β (Figure 5A), indicating that both kinase 
pathways were blocked by ZD1839 in these cells. In A549 (Figure 5B) and 
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SW1573 cells (Figure 5C), phosphorylation of Erk and p90rsk were only partially 
inhibited, but showed a dose-dependent decline of Akt and GSK3β 
phosphorylation. In contrast, H460 cells showed dose-dependent reduction of 
Erk and p90rsk phosphorylation, but only in part of Akt and GSK3β 
phosphorylation (Figure 5D). In the H1703 cell line, no effects of ZD1839 were 
observed on the phosphorylation status of Erk, p90rsk, Akt and GSK3β (Figure 
5E). The dose-dependent effect shows that inhibition of the Erk and Akt kinase 
pathways by ZD1839 is the consequence of EGFR blocking. Furthermore, these 
data confirm that at least one of the kinase pathways involving Erk and Akt is 
persistently active in the presence of ZD1839 in the NSCLC cells, whereas both 
pathways are effectively blocked in A431 cells. 
 
Figure 5.  Dose-dependent inhibition of Erk and Akt kinase pathways by ZD1839. Serum-
starved A431 cells (A) and NSCLC cells (B-E) were treated with different concentrations of 
ZD1839 (0, 0.05, 0.1, 0.25, 0.5, and 1 µM) for 2 h prior to stimulation with 10 ng/ml EGF for 5 min. 
Equal amounts of protein were separated by SDS-PAGE and transferred to nitrocellulose 
membranes, which were immunostained for phosphorylated and total Erk and Akt, 
phosphorylated p90rsk and phosphorylated GSK3β. As a control for equal protein loading, 
membranes were stripped and reprobed with antibodies recognising β-actin. BLOCKED: effective 
inhibition of the Erk or Akt pathway by ZD1839; ACTIVE: persistent activity of the Erk or Akt 
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Simultaneous inhibition of the MEK and PI3K pathways results in effective 
inhibition of growth and apoptosis 
 The above results suggest that persistent activity of the MEK and/or PI3K 
pathway contributes to the resistance of NSCLC cells to EGFR antagonists. To 
independently investigate the role of MEK and PI3K in proliferation, we 
determined the effect of U0126 and LY294002 on the growth of A431, A549, 
and H460 cells. As single agents, both inhibitors induced a dose-dependent 
growth inhibition that was similar in all cell lines in a 72 h MTT assay (Fig. 6A-C), 
demonstrating a role of both kinase pathways in the proliferation of these cells. 
When cells were treated with a combination of U0126 and LY294002, the effect 
on growth was at least additive in all cell lines (Fig. 6A-C), suggesting an 
independent role of the MEK and PI3K pathway in proliferation. When 
compared with U0126 and LY294002 as single agents or in combination, 
ZD1839 was more effective to inhibit the growth of A431 cells (Fig. 6A), 
indicating that ZD1839 is more potent to inhibit its target than U0126 or 
LY294002, and that A431 cells are largely dependent on EGFR activity for their 
growth. In contrast, treatment of NSCLC cells with U0126 and/or LY294002 
produced a more pronounced inhibition of cell growth than treatment with 
ZD1839 (Fig. 6B-C). This can be explained by the fact that ZD1839 specifically 
blocks EGFR-dependent signalling, while activation of downstream pathways in 
the presence of EGFR inhibitors is still possible by enhanced activity of proteins 
such as Ras or PI3K 34,35, or via other receptors that may be activated by growth 
factors or hormones in the serum 22. U0126 and LY294002 directly inhibit the 
MEK or PI3K pathway, thereby blocking EGFR-dependent and -independent 
signalling and inducing stronger antiproliferative effects. In addition, despite 
the selectivity of the MEK and PI3K inhibitors, we cannot rule out their potential 
effects on other targets involved in proliferation, in particular at higher 
concentrations 36. 
 In addition, we used U0126 and LY294002 to determine the role of the 
MEK and PI3K pathways on apoptosis in A431, A549, and H460 cells. As shown 
earlier, ZD1839 induced a 2- to 3-fold increase of A431 cells with hypodiploid 
DNA, while no effect was observed in the A549 or H460 cell line (Fig. 1; Fig. 6D-
F). Neither U0126 nor LY294002 induced changes in the sub-G1 population as 
single agent in any of the cell lines, while the combination of both agents 
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induced an increase in the sub-G1 population in A431 as well as the lung cancer 
cells to a level that was similar to the sub-G1 population induced by ZD1839 in 
A431 cells (Fig. 6D-F). These data indicate that the inhibition of the MEK and the 
PI3K pathway in A431 cells by ZD1839 can explain the cell death induced in 
these cells, and support the view that the persistent activity of at least one of 
these pathways may protect the NSCLC cells from ZD1839-induced apoptosis.  
Figure 6.  Effective growth inhibition and induction of apoptosis in cells with inhibited MEK 
and PI3K. (A-C) Growth curves of A431, A549, and H460 cells treated with different 
concentrations of ZD1839, U0126, LY294002, or a combination of U0126 and LY294002, with a 
ratio of 1:2. Growth was represented as % of untreated cells, analysed by MTT assay at 72h. The 
plots were fitted using Sigma plot software (four-parameter logistic curve). Similar results were 
obtained in at least three independent experiments. (D-E) Analysis of the sub-G1 population 
induced by ZD1839 (1 µM), U0126 (10 µM), LY294002 (30 µM), or a combination of U0126 and 
LY294002. A431, A549, and H460 cells were treated with the kinase inhibitors for 72 h, 
subsequently stained with propidium iodide, and analysed by flow cytometry. 
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In this study, we show that treatment of NSCLC cell lines with EGFR 
inhibitors induce differential antiproliferative effects, although the effect on 
growth is limited when compared to the control A431 cell line. In the highly 
sensitive A431 cell line and to a lesser extent also in A549 cells, the growth 
inhibitory effect of the EGFR antagonists correlates with an arrest of cells in the 
G1/G0-phase of the cell cycle, while the cell cycle is unaffected in the more 
resistant lung cancer cell lines (Fig. 1). These results are consistent with earlier 
reports, showing that antiproliferative effects of ZD1839 or C225 correlate with 
a G1/G0-phase cell cycle arrest in cell lines derived from breast and head and 
neck tumors 14,26. 
We demonstrate that treatment with EGFR-inhibitors induces a modest 
apoptotic response in A431 cells, but does not affect the survival of NSCLC cells 
(Table 1; Fig. 3). Comparable amounts of apoptosis have been reported for 
several other cell lines treated with ZD1839 or C225 12,14, while effective 
induction of apoptosis by EGFR-targeted agents has been reported in only a few 
cell lines 16,17. In line with an earlier report demonstrating that ZD1839 induces 
apoptosis by activating the pro-apoptotic Bcl-2-family member BAD in 
mammary cells 16, we found that overexpression of Bcl-2 prevents ZD1839- and 
C225-induced cell death in A431 cells. We further show that caspases 
contribute, at least in part, to the cytotoxity of ZD1839 in A431 cells. 
We investigated molecular differences that may underlie the variable 
sensitivity of A431 and NSCLC cells to anti-EGFR agents. It has been reported 
that cells with high expression of EGFR 21,23 or ErbB2 22,23,26 are particularly 
sensitive to ZD1839, suggesting that abundant expression of EGFR or ErbB2 is 
required to modulate sensitivity. However, Moasser et al also demonstrated that 
high endogenous EGFR expression per se does not determine sensitivity to EGFR 
inhibitors 23. Since EGFR and ErbB2 are part of a large signalling network 4, a 
number of factors rather than expression levels of the receptors alone may 
determine the sensitivity of a cell to EGFR inhibitors. In support of this view, we 
found that the sensitivity to the anti-EGFR agents within the panel of lung 
cancer cells differed significantly, although all expressed similar, moderate 
protein levels of EGFR compared to the highly EGFR-expressing A431 cell line, 
Effect of EGFR inhibition in NSCLC cell lines 
 
 69
whereas the ErbB2 expression levels were similar in all cell lines, including A431. 
This indicates that neither EGFR nor ErbB2 expression levels correlate with 
sensitivity to EGFR inhibitors in NSCLC cells. 
Next, we determined the activation status of the MEK and the PI3K 
pathway, two major intracellular signalling pathways activated by the EGFR. 
Sensitivity to EGFR-inhibitors was found to correlate with persistent activity of 
these pathways in presence of ZD1839 in the panel of NSCLC cell lines, whereas 
they are effectively blocked in the A431 cell line (Fig. 5). In line with this, 
Brognard et al recently showed that Erk and Akt were constitutively active in the 
majority of NSCLC cell lines deprived of serum 37,38. Moreover, our results 
showing more effective antiproliferative effects when both pathways are 
blocked, indicate that the MEK and PI3K pathways may independently 
contribute to the proliferation of these cells (Fig. 6B-C). These data are in line 
with previous evidence showing that intrinsically active Erk 30 and Akt 23 
correlate with reduced antiproliferative activity of ZD1839 in several epithelial 
tumor cell lines, while the growth inhibitory effect of the HER2-targeted Mab 
herceptin is prevented in breast cancer cells ectopically overexpressing an 
active mutant of Akt 39. 
In addition to their contribution to cell proliferation, persistently active 
Erk and Akt pathways may protect cells from apoptosis induced by EGFR-
targeted agents. Earlier reports demonstrated that cells transfected with active 
mutants of members of the MEK/Erk or PI3K/Akt pathway bypassed apoptosis 
induced by ZD1839 16 or herceptin 39. We found that chemical inhibition of 
either MEK or PI3K did not generate apoptosis of A431 or NSCLC cells (Fig. 6C-F), 
which was recently also shown in the A549 and other NSCLC cell lines 37,38. In 
contrast, disabling the MEK and the PI3K pathway resulted in the induction of a 
modest apoptotic response in the A431 and lung cancer cell lines, similar to the 
amount of apoptosis induced by ZD1839 in A431 cells (Fig. 6C-F). These data 
further support the idea that persistently active MEK and PI3K pathways, which 
are present in the NSCLC cell lines, account for the unaffected survival of these 
cells in the presence of anti-EGFR agents. 
The limited effect observed in vitro contrasts with some in vivo studies 
reporting complete regressions of A431-derived tumors in mice treated with 
ZD1839 or C225, and 70-80% growth inhibition of A549-derived tumors in 
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ZD1839-treated mice 15,24,40. Mechanisms that are only active in vivo may explain 
the more effective antitumor activity in vivo compared to the limited 
antiproliferative effects in vitro, such as observed in A549 cells. First, C225 and 
ZD1839 can inhibit angiogenesis, which has been proposed to be the result of 
reduced secretion of angiogenesis factors 41-45, while anti-EGFR agents can also 
directly inhibit the growth and cell-cell interaction of endothelial cells 24,46. 
Second, C225 was shown to inhibit metastasis of bladder carcinoma xenografts 
44, demonstrating the implication of EGFR signalling in cell migration and 
invasion 47,48.  
 The results presented here, showing that constitutively active Erk and 
Akt could contribute to resistance to anti-EGFR treatment, may have important 
clinical relevance. To select for patients that may benefit from anti-EGFR 
therapy, it may be important to identify tumors that do not carry intrinsically 
active Erk or Akt. Immunohistochemical analysis of tumors for activated Erk and 
Akt may predict response to ZD1839 and C225, and will give more insight if 
constitutively activated Erk and/or Akt correlate with higher resistance to anti-
EGFR treatment in patients. In fact, activated Erk has been correlated with EGFR 
activity in tumors 22,49 and is downregulated in the skin from cancer patients 
treated with ZD1839 50, suggesting that activated Erk can be used as a marker 
for EGFR activity in vivo. On the other hand, anti-EGFR treatment in combination 
with specific inhibitors targeting kinase pathways via MEK or PI3K, some of 
which are now tested in preclinical and clinical studies 51, might result in 
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In this study, we have characterized a panel of NSCLC cell lines with 
differential sensitivity to gefitinib for activating mutations in egfr, pik3ca, and k-
ras, and basal protein expression levels of PTEN. The egfr mutant NSCLC cell line 
H1650 as well as the egfr wild type cell lines H292 and A431 were highly sensitive 
to gefitinib treatment, indicating that other factors determine gefitinib 
sensitivity in egfr wild type cells. Activating k-ras mutations were specifically 
detected in gefitinib-resistant cells, suggesting that the occurrence of k-ras 
mutations is correlated with resistance to EGFR antagonists. No pik3ca mutations 
were detected within the panel of cell lines, and PTEN protein expression levels 
did not correlate with gefitinib sensitivity. Gefitinib effectively blocked Akt and 
Erk phosphorylation in two gefitinib-sensitive NSCLC cell lines, further 
supporting our previous findings that persistent activity of the PI3K/Akt and/or 
Ras/Erk pathways is associated with gefitinib-resistance of NSCLC cell lines. 
Gefitinib-resistant NSCLC cell lines, showing EGFR-independent activity of the 
PI3K/Akt or Ras/Erk pathways, were treated with gefitinib in combination with 
specific inhibitors of mTOR, P13K, Ras, and MEK. Additive cytotoxicity was 
observed in A549 cells co-treated with gefitinib and the MEK inhibitor U0126 or 
the farnesyl transferase inhibitor SCH66336 and in H460 cells treated with 
gefitinib and the PI3K inhibitor LY294002, but not in H460 cells treated with 
gefitinib and rapamycin. These data suggest that combination treatment of 
NSCLC cells with gefitinib and specific inhibitors of the PI3K/Akt and Ras/Erk 
pathways may provide a successful strategy. 




 The EGFRII (ErbB1, HER1) is the prototypic member of the ErbB family of 
RTKs, which further consists of ErbB2-4 (HER2-4). The ErbB receptors share a 
similar protein structure, consisting of an extracellular ligand binding domain, a 
single transmembrane domain and an intracellular C-terminal domain with 
tyrosine kinase activity. Upon specific binding of EGF-like ligands to the 
extracellular domain, ErbB receptors dimerize, either as homodimers or as 
heterodimers, and undergo autophosphorylation at specific tyrosine residues 
within the intracellular domain. These phosphorylated tyrosines serve as 
docking sites for adapter molecules such as Grb2 and the p85 subunit of PI3K, 
which activate downstream signalling pathways. These pathways, including the 
Ras/MAPK and Akt/mTOR kinase cascades, in turn, regulate transcription factors 
and other proteins involved in cell proliferation, survival, motility, and 
differentiation 1 (Figure 1). Aberrantly high EGFR activity is common in several 
tumor types, including NSCLC, and correlates with a more aggressive disease, 
resistance to chemotherapy, and poor patient prognosis. 
 Monoclonal antibodies to the extracellular domain of EGFR, such as 
cetuximab, and EGFR tyrosine kinase inhibitors, including gefitinib and erlotinib, 
specifically block EGFR activity. In preclinical studies, these agents have been 
demonstrated to inhibit cell proliferation and tumor growth and, in some 
models, to induce cell death and tumor shrinkage 2-5. Many preclinical studies 
have demonstrated anti-tumor effects of cetuximab and gefitinib in 
combination with other anticancer therapies, in particular chemotherapeutic 
agents and radiation 2,3,5. In clinical settings, single agent anti-EGFR therapy 
resulted in significant anti-tumor activity in several cancer types, including in 10-
20 % of NSCLC patients 6. As a result of this, gefitinib and erlotinib has been 
registered for the second and third line treatment of NSCLC in the US and other 
countries. In contrast to the promising preclinical data, no additional effects of 
EGFR inhibitors have been observed in four large phase III clinical trials in NSCLC 
patients, in which gefitinib or erlotinib were added to standard chemotherapy 6-
8. 
 Recently, a strong correlation has been reported between somatic 
mutations in the egfr gene and dramatic clinical response to gefitinib in patients 
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with NSCLC 9,10. Conversely, we and others have shown that persistent activity of 
the Ras/Erk and PI3K/Akt kinase pathways contributes to resistance of NSCLC 
cells to EGFR inhibitors 4,11,12. Growth factor independent activity of EGFR-
downstream pathways may be due to several tumor-associated alterations, 
including activating mutations in the k-ras 13 or pik3ca 14 genes, or loss of the 
tumor suppressor pten 15. 
 In this study, we have characterized a panel of NSCLC cell lines for specific 
mutations in the EGFR, k-ras, and PI3K genes and we evaluated basal protein 
expression and activation status of EGFR pathway components, including PTEN. 
The relationship between the presence of these alterations and the ability of 
gefitinib to inhibit the EGFR-downstream pathways was assessed. Finally, in 
those cell lines showing EGFR-independent activity of the PI3K/Akt or Ras/Erk 
pathways, we investigated the effect of gefitinib in combination with specific 





Figure 1.  The EGF receptor pathway and the action sites of specific kinase- and farnesyl-
transferase-inhibitors. Schematic representation of major components of the EGF receptor 
pathway. Drugs that have been used in this study interfere at specific sites within this pathway, 
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Materials and Methods 
 
Cells and culture conditions 
 RPMI 1640 (containing 2 mM L-glutamine) and DMEM were used as culture media and were 
supplemented with 10 % heat-inactivated fetal calf serum (Gibco BRL, Life technology, Breda, 
The Netherlands), 50 iu/ml penicillin and 50 g/ml streptomycin. The human NSCLC cell lines 
NCI-H460 (H460), NCI-H1703 (H1703), NCI-H292 (H292), NCI-H1650 (H1650) and A549 cells were 
cultured in RPMI 1640, the human NSCLC cell line SW1573 and the epidermoid carcinoma cell 
line A431 were cultured in DMEM. Cells were grown at 37° C in a humidified atmosphere with 5 
% CO2. Cells from exponentially growing cultures were used in all experiments. 
 
Table 1. Primers used for nested amplification of genomic DNA sequences of EGFR, PIK3CA, 
and k-ras. 
 
DNA isolation, PCR and primers 
 Total genomic DNA was isolated from cell lines using DNA STAT-60TM  (Tel-Test Inc, 
Friendswood, TX), according to the manufacturer’s protocol. Nested PCRs were carried out using 
the external and internal primers detailed in Table 1. Sequencing of PCR products was 
performed using the BigDyeTM Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA), the M13 primers 5’-TGTAAAACGACGGCCAGT-3’ (forward) and 5’-



































































































CAGGAAACAGCTATGACC-3’ (reverse) and the ABI PRISMTM 310 Genetic analyzer (Applied 
Biosystems). The mutations found were confirmed by sequencing independent PCR products. 
 
Chemicals 
 The EGFR-TKI gefitinib (IressaTM, ZD1839) was kindly provided by AstraZeneca (Macclesfield, 
UK) as a pure substance, which was diluted in dimethylsulfoxide (DMSO) to a stock 
concentration of 20 mM. The farnesyl transferase inhibitor SCH66336 (provided by Schering-
Plough, Kenilworth, NJ), and the kinase inhibitors rapamycin (LC Laboratories, Woburn, MA), 




 For cellular survival assays 5 x 103 cells were plated into flat bottom 96-well plates (Costar, 
Corning, NY). After 24 h, the growth medium was replaced by medium containing 0.5 % fetal calf 
serum when indicated. Subsequently, various concentrations of the indicated drugs were added 
and the cells were incubated for an additional 72 h.  Next, 10 % (v/v) of a solution of 5 mg/ml 
MTT (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) was added to each 
well and incubated for 3 h at 37o C. Plates were centrifuged for 5 min at 1200 rpm and the 
medium was carefully discarded. The formed formazan crystals were dissolved in 100 µl DMSO, 
and absorbance was determined at 540 nm using a Spectra Fluorimeter (Tecan, Salzburg, 
Austria). Absorbance values were expressed as the percentage of the untreated controls. The 




 SDS-PAGE and Western Blotting was performed as previously described 4. In short, whole 
cell lysates were denatured in sample buffer containing SDS, and equal amounts of total protein 
were separated on 8-15 % SDS-poly-acrylamide gels and transferred to nitrocellulose 
membranes. After blocking with 5 % non-fat dry milk, the membranes were incubated overnight 
at 4° C with the primary antibodies as indicated. The following antibodies were used: anti-PTEN, 
anti-phospho-EGFR (Tyr1068), anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-Erk, anti-Erk, 
anti-phospho-p70s6K (all from Cell Signaling Technology), anti-EGFR (Ab-12) (Neomarkers, 
Fremont, CA), and anti--actin (Sigma, Zwijndrecht, the Netherlands). The following day, the 
membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary 
antibodies, and detection was performed using enhanced chemiluminescence reagent 
(Amersham Biosciences, Amersham, UK). 
 
Statistics 
ANOVA analysis was used to evaluate potential differences between the single agent 
treatment groups and the combination treatment groups. P-values resulted from the use of the 
Tamhane’s T2 test (assumed unequal variances). 




Characterization of egfr, k-ras, and pik3ca gene status and PTEN protein 
levels in a panel of cell lines 
 Growth factor-independent activation of the Akt and Erk pathways can be 
due to activating mutations in the k-ras 13 or the pik3ca 14 genes, respectively. 
Recently, it has been demonstrated that specific activating mutations in the egfr 
gene are predictive for a clinical response to gefitinib in NSCLC patients 9,10. To 
investigate the implications of EGFR, k-ras, and PIK3CA mutations on gefitinib-
response, we characterized a panel of NSCLC cell lines and the gefitinib-sensitive 
A431 vulval carcinoma cell line for activating mutations in these genes. Only the 
H1650 cell line, included as a positive control 16, was found to have a mutation in 
the egfr gene, whereas all other tested cell lines, including the gefitinib-sensitive 
A431 and H292 cells, were egfr wild type (Table 2). K-ras mutations were found in 
three of the tested cell lines, which were all found to be relatively resistant to 
treatment with gefitinib (Table 2). The presence of mutations in the k-ras gene 
was associated with a lack of Erk response to gefitinib treatment in A549 and 
SW1573 cells, which harbor a mutation in codon 12 of k-ras (Table 2). This may 
have been expected due to growth factor-independent activity of mutated k-
Ras protein. In contrast, gefitinib efficiently reduced Erk phosphorylation in the 
H460 cell line, which harbors a mutation in codon 61 of k-ras, indicating that k-
ras mutations do not always result in EGFR-independent Erk activity. None of the 
cell lines harbored mutations in hotspot regions of the pik3ca gene (Table 2), 
encoding the p110α catalytic subunit of PI3K 14. Depletion of the tumor 
suppressor pten can also increase growth factor-independent activity of the 
PI3K/Akt pathway 15 and causes resistance of tumor cell lines, including NSCLC 
cells, to gefitinib 11,17. As analyzed by Western blotting, basal protein expression 
levels of PTEN varied between the different cell lines (Figure 2). However, no 
relationship was found between PTEN expression levels and gefitinib sensitivity 





Table 2. Characterization of EGFR, k-ras, and PIK3CA genes in a panel of cell lines in 
comparison to gefitinib sensitivity and p-Erk and p-Akt response to gefitinib.  
1 IC50 concentrations for gefitinib and p-Erk and p-Akt response to gefitinib have been partially 
reported previously 4. 
2 p-Erk, phosphorylated Erk; p-Akt, phosphorylated Akt 
3 Blocked, effective inhibition of phosphorylated Erk or Akt by gefitinib; Active, persistent 
phosphorylation of Erk or Akt after treatment with gefitinib. 
4 Wt, wild-type; Mut (changed amino acid), mutated; Del, deletion. 
5 PTEN protein expression levels relative to H460, analyzed by quantifying the Western Blot data 
shown in Figure 2, normalized to β-actin. 
 
Figure 2.  Characterization of basal PTEN protein expression levels in a panel of NSCLC cell 
lines with different sensitivity to gefitinib. Total protein expression levels of PTEN were 
analysed by Western blotting using a polyclonal antibody, raised against human PTEN-derived 
peptides. Blots were reprobed for β-actin as a control for equal protein loading. 
 
The Akt and Erk pathways are effectively blocked by EGFR antagonists in 
gefitinib-sensitive NSCLC cell lines 
 Previously, we reported that persistent activity of the PI3K/Akt and/or 
Ras/MEK/Erk pathways is associated with higher resistance of NSCLC cell lines to 
EGFR antagonists 4. We provide here further support for our previous finding by 
extending the panel of cell lines to include two gefitinib-sensitive NSCLC cell 
lines, H292 and H1650 (Table 2). Treatment of these cells with gefitinib 
effectively inhibited EGF-induced phosphorylation of EGFR, Akt and Erk (Figure 
3A, B; lane 3) in contrast to gefitinib-resistant cells (Table 2). In gefitinib-sensitive 
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cell lines, the EGFR-specific antagonistic antibody C225 inhibited EGF-induced 
EGFR phosphorylation, but did not affect Akt and Erk phosphorylation, or 
blocked it less effectively than gefitinib (data not shown). As expected, the PI3K 
inhibitor LY294002 and the MEK inhibitor U0126 completely abrogated Akt or 
Erk phosphorylation, respectively (Figure 3A, B; lanes 4 and 5).  
 
Figure 3.  Gefitinib blocks the Akt- and Erk-pathways in gefitinib-sensitive NSCLC cell lines. 
Western blot analysis of gefitinib-sensitive NSCLC cell lines H292 (A) and H1650 (B) that were 
treated with ZD1839 (1 µM), U0126 (10 µM), or LY294002 (30 µM) for 2 h before exposure to EGF 
(10 ng/ml) for 5 min. Protein levels of total and phosphorylated (p) EGFR, Akt, and Erk were 
analysed. 
 
Enhanced cytotoxic effect of gefitinib with the PI3K inhibitor LY294002 but 
not with rapamycin in H460 cells 
 We hypothesized that if EGFR-independent activity of the PI3K/Akt pathway 
contributes to gefitinib-resistance in NSCLC cell lines 4 (table 2), anti-EGFR 
treatment in combination with specific inhibitors of the PI3K pathway may result 
in additional cytotoxic effects in NSCLC cell lines such as H460, in which the PI3K 
pathway is not effectively blocked by gefitinib. To test this hypothesis, growth 
inhibition was determined in H460 cells treated with gefitinib in combination 
with the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin, which act at 
different sites in the PI3K/Akt pathway (Figure 1). Combined treatment of two 
concentrations of LY294002 and gefitinib resulted in reduced growth of H460 
cells compared to treatment with single agents (Figure 4A). As serum may 
activate growth factor pathways parallel to the EGFR pathway, bypassing the 
inhibition of EGFR, Ras, or MEK, growth inhibition assays were also carried out 
under low (0.5 %) serum conditions. Co-treatment with gefitinib and the two 
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these conditions (Figure 4A). Although this reduction of cell growth was not 
significantly different from treatment with single agents, these data suggest that 
gefitinib and LY294002 have at least an additive interaction. In contrast to 
LY294002, addition of rapamycin to gefitinib did not result in enhanced 
cytotoxicity in H460 cells grown under high or low serum conditions (Figure 4B). 
 To verify that the observed growth effects of gefitinib in combination with 
rapamycin or LY294002 were due to the inhibition of PI3K and/or mTOR in 
addition to EGFR, we analyzed the activation status of downstream components 
by Western blotting. As shown before 4, gefitinib completely inhibited basal and 
EGF-induced phosphorylation of EGFR and Erk, whereas EGF-induced 
phosphorylation of Akt and p70s6K, downstream of Akt, was only inhibited to 
levels observed in untreated cells (Figure 4C, lanes 3 and 4). Treatment with 
rapamycin completely and specifically eradicated phosphorylation of the mTOR 
substrate p70s6K, but not of Erk or the upstream kinases EGFR and Akt (Figure 
4C, lanes 5 and 6). Addition of gefitinib to rapamycin removed EGF-induced 
phosphorylation of EGFR and Erk in addition to p70s6K, but not of Akt (Figure 
4C, lanes 7 and 8). The PI3K inhibitor LY294002 specifically blocked 
phosphorylation of Akt and p70s6K (Figure 4C, lanes 9 and 10), while addition of 
gefitinib to LY294002 effectively inhibited EGFR, Akt, Erk, and p70s6K 
phosphorylation (Figure 4C, lanes 11 and 12). Interestingly, EGF stimulation 
induced a rapid downregulation of total EGFR in H460 cells, which was 
efficiently blocked by gefitinib (Figure 4C). 
 
Additive cytotoxic effects of gefitinib with inhibitors of the Ras/MEK 
pathway in A549 cells 
 In addition to persistent activity of the PI3K pathway, EGFR-independent 
activity of the Ras/Erk pathway contributes to gefitinib-resistance in NSCLC cell 
lines 4. Therefore, we hypothesized that anti-EGFR treatment in combination 
with specific inhibitors of the Ras/Erk kinase pathway may result in additional 
cytotoxic effects in NSCLC cell lines, such as A549 and SW1573 cells, that 
maintain Erk phosphorylation after gefitinib treatment (see Table 2). To test this 
hypothesis, cell growth was determined in A549 and SW1573 cells treated with 
gefitinib in combination with the specific MEK inhibitor U0126 or the farnesyl 
transferase inhibitor SCH66336, which inhibits farnesylation and activation of  
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Figure 4.  Combined inhibition of the EGF receptor and the PI3K/Akt/mTOR pathway in 
H460 cells. The NSCLC-derived H460 cell line was treated with two different concentrations of A, 
LY294002 or B, rapamycin with or without gefitinib (1 µM) for 72 h. Experiments were carried out 
under low (0.5 %) and high (10 %) fetal calf serum conditions. The bars represent the mean 
absorbance (arbitrary units) and standard error obtained in least three independent MTT assays 
carried out in triplo (*, P ≤ 0.05; **, P ≤ 0.01, Tamhane’s T2 test). C, Western blot analysis of H460 
cells treated with gefitinib (ZD; 1 µM), rapamycin (rapa; 50 nM), LY294002 (LY; 30 µM), or 
combinations for 2 h before exposure to EGF (10 ng/ml) for 5 min. Protein levels of total and 
phosphorylated (p) EGFR, Akt, and Erk were analysed. 
 
Ras proteins 18. Addition of gefitinib to two different concentrations of U0126 
(Figure 5A) or SCH66336 (Figure 5B) reduced the growth of A549 cells compared 
to treatment with single agents under high as well as low serum conditions. 
Statistically significant effects were observed only in cells treated with 8 µM 
U0126 and gefitinib (1µM) under low serum conditions and in cells treated with 
1 µM SCH66336 and gefitinib (1 µM) under high serum conditions, indicating 
that the efficacy is dependent on the used conditions. In contrast to A549 cells, 
no enhanced effects of gefitinib on U0126- or SCH66336- induced cytotoxicity 
were observed in SW1573 cells under both serum conditions (data not shown). 
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 To confirm that the observed cytotoxic effects were due to inhibition of Erk 
phosphorylation, the effects of SCH66336 and U0126 on the activation status of 
EGFR downstream pathway components were examined. U0126 specifically and 
effectively inhibited Erk phosphorylation and did not affect the phosphorylation 
of EGFR or Akt (Figure 5C, lanes 9 and 10). Unexpectedly, SCH66336 induced Erk 
phosphorylation to a similar extent as in EGF-treated cells, while stimulation of 
SCH66336-treated cells with EGF even further increased Erk phosphorylation 
(Figure 5C, lanes 5 and 6). Co-treatment of cells with gefitinib did not affect 
SCH66336-induced Erk phosphorylation, but blocked the EGF-enhanced Erk 
phosphorylation (Figure 5C, lanes 7 and 8). SCH66336-induced Erk 
phosphorylation was also observed in SW1573 cells (data not shown). 
 
Figure 5.  Combined inhibition of the EGF receptor and the Ras/MEK pathway in A549 cells. 
A, B, A549 cells were treated with two different concentrations of A, U0126 or B, SCH66336 with 
or without gefitinib (1 µM) for 72 h. Experiments were carried out under low (0.5 %) and high (10 
%) fetal calf serum conditions. The bars represent the mean absorbance (arbitrary units) and 
standard error obtained in least three independent MTT assays carried out in triplo (*, P ≤ 0.05; 
**, P ≤ 0.01, Tamhane’s T2 test). C, Western blot analysis of A549 cells treated with gefitinib (ZD; 1 
µM), SCH66336 (SCH; 8 µM), U0126 (U; 8 µM), or combinations for 2 h before exposure to EGF (10 
ng/ml) for 5 min. Protein levels of total and phosphorylated (p) EGFR, Akt, and Erk were analysed. 
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 We have previously reported that persistent activity of the PI3K/Akt and/or 
Ras/Erk pathways is associated with gefitinib-resistance of NSCLC cell lines and 
that simultaneous inhibition of PI3K/Akt and MEK/Erk reduces tumor cell 
survival more effectively than inhibition of each pathway alone 4. Here, we 
provide further support for these findings by demonstrating that gefitinib 
effectively blocks Akt and Erk phosphorylation in two gefitinib-sensitive NSCLC 
cell lines. 
 We carried out a detailed mutational and expression analysis of key genes 
and proteins that may be involved in modulating the response to gefitinib. As 
expected, we observed that the NSCLC cell line H1650, harboring a mutation in 
egfr, is sensitive to gefitinib treatment. However, we found that the other 
gefitinib-sensitive NSCLC cell line, H292, and A431 cells do not harbor activating 
mutations in the egfr gene. This finding suggests that other factors determine 
the strong EGFR-dependency in these EGFR wild type cell lines. In fact, the 
gefitinib-sensitive A431 cell line is known to harbor about 30 copies of the egfr 
gene within its genome 19, resulting in excessive EGFR protein expression 4. 
H292 cells also express relatively high levels of EGFR (data not shown), although 
this cell line has not been investigated for egfr gene amplifications. To select 
patients that benefit from anti-EGFR therapy in the clinic, it will be important to 
identify markers that can predict the sensitivity of egfr wild type tumors. For 
example, it could be possible that within the subset of egfr wild type tumors 
EGFR expression levels are predictive for outcome. 
 Mutational analysis of genes encoding EGFR downstream components 
revealed that activating k-ras mutations were only detected in gefitinib-resistant 
NSCLC cell lines, whereas no mutations were observed in gefitinib-sensitive cell 
lines. This, in contrast to other reports 20, suggests that occurrence of k-ras 
mutations is correlated with resistance to EGFR antagonists. None of the cell 
lines harbored mutations in hotspot regions of the pik3ca gene, encoding the 
p110α catalytic subunit of PI3K, which have been reported to occur at low 
frequency in NSCLC 14. In contrast to other reports 11,17, our data suggest that 
absence of the tumor suppressor pten is not necessarily a factor of resistance to 
gefitinib, at least in the presence of an egfr mutation, as we observed a lack of 
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PTEN protein expression in the gefitinib-sensitive, egfr-mutant H1650 cell line. 
Treatment with gefitinib efficiently inhibited Akt phosphorylation in these cells, 
showing that Akt phosphorylation is still EGFR-dependent in these PTEN-
deficient cells. Conversely, Akt phosphorylation was inefficiently inhibited by 
gefitinib in H460 cells, which express relatively high PTEN protein levels. 
 Further supporting our view that simultaneous inhibition of Akt and Erk 
results in stronger cytotoxic effects than inhibition of each pathway alone, we 
demonstrate here that treatment with gefitinib in combination with specific Ras, 
MEK or PI3K inhibitors results in enhanced cytotoxic effects in gefitinib-resistant 
NSCLC cell lines. For example, co-treatment of H460 cells treated with gefitinib 
and the PI3K inhibitor LY294002 or co-treatment of A549 cells with gefitinib and 
the MEK inhibitor U0126 resulted in enhanced cytotoxicity. In contrast to the 
PI3K inhibitor LY294002, the mTOR inhibitor rapamycin, acting downstream of 
PI3K and Akt, did not enhance the cytotoxic effects of gefitinib in H460 cells, 
although rapamycin effectively inhibited the phosphorylation of the mTOR 
substrate p70s6K. These data indicate that enhancement of gefitinib-induced 
cytotoxicity in H460 cells requires additional inhibition of Akt but is independent 
of inhibition of the downstream mTOR pathway. On the other hand, treatment 
of A549 cells with the farnesyl transferase inhibitor SCH66336, thought to inhibit 
Ras activity 18, enhanced gefitinib-induced cytotoxicity. However, the additive 
interaction between SCH66336 and gefitinib appears to be independent from 
Erk inhibition, as SCH66336 unexpectedly induced an increase of Erk 
phosphorylation in this cell line, in contrast to previously observed SCH66336-
induced decrease of Erk phosphorylation in glioma cell lines and Ras-
transformed Rat2 fibroblasts 21,22. The exact molecular mechanism underlying 
the additive interaction between gefitinib and SCH66336 requires further 
investigation.  
 Although the enhanced cytotoxicity of gefitinib in combination with Ras, 
MEK or PI3K inhibitors appears to be largely independent of factors present in 
the serum, it may be affected by cell type-specific differences. Thus, similar 
effects were observed in H460 and A549 cells in high or low serum conditions, 
but no additive effects of combination treatments were noted in SW1573 cells. 
 Together, our data suggest that treatment of NSCLC cell lines with 
combinations of gefitinib and specific inhibitors of the PI3K/Akt or Ras/Erk 
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pathways is a successful strategy. Moreover, to our knowledge we are the first to 
show that an EGFR antagonist enhances the cytotoxicy of a farnesyl transferase 
inhibitor in NSCLC cells. Although the efficacy and tolerability of the 
combinations have to be tested more extensively in preclinical models, our 
results can be meaningful in the clinic, as many specific signal transduction 
inhibitors are being developed for clinical use. In fact, small molecule inhibitors 
that specifically target various steps of the PI3K-Akt and Ras-MAPK pathways 
have entered clinical trials, including farnesyl transferase inhibitors, MEK 
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Purpose:  The efficacy of the EGFR tyrosine kinase inhibitor gefitinib was assessed in a 
phase II study in patients with advanced esophageal cancer. Several biological features 
were investigated as potential markers of gefitinib activity. 
Patients and methods:  Patients with advanced esophageal cancer, who had failed one 
line of prior chemotherapy, were given gefitinib 500 mg/day. Response was evaluated 
every 8 weeks. Tumor material obtained before gefitinib treatment was investigated for 
gene mutations in EGFR, k-ras, and PIK3CA, protein expression levels of EGFR, p-Akt, and 
p-Erk, and EGFR gene amplification. 
Results:   Of the 36 enrolled patients, one achieved a partial response (2.8%), 10 had 
stable disease (27.8%), 17 (47.2%) progressed on treatment, while 8 (22.2%) were not 
evaluable for response. The progression-free survival was 59 days and the median 
overall survival was 164 days. Although EGFR or PIK3CA mutations were absent, k-ras 
mutations were found in two patients with progressive disease. High EGFR gene copy 
number was identified in two patients experiencing partial response or progressive 
disease. A higher disease control rate (response plus stable disease) was observed in 
female (P=0.038) and in patients with SCC (P=0.013) or high EGFR expression (P=0.002).  
Conclusion:  Gefitinib has a modest activity in second-line treatment of advanced 
esophageal cancer. However, the patient outcome was significantly better in female 
and in patients demonstrating high EGFR expression or SCC histology. The selection of 
esophageal cancer patients for future studies with EGFR-TKIs based on the level of EGFR 
expression in their tumors or SCC histology should be considered. 




Esophageal cancer is a disease with a high mortality, and is the fastest growing 
malignancy in the United States 1. The survival depends on the stage of the disease. 
Surgical resection is the treatment of choice for early lesions. In recent years, possibly 
due to introduction of broader use of flexible endoscopes, tumors that are confined to 
mucosa and submucosa are more frequently diagnosed 2. However, even when surgery 
can be performed, survival is still poor, with only 5-20% alive at 5 years 3. The 
introduction of neoadjuvant chemotherapy and chemoradiotherapy has improved 
survival in several series, however there is still no consensus on whether neoadjuvant 
therapy is indicated in all operable cases 4. When patients are not operable or they 
relapse after operation, chemotherapy can induce response rates in about 30-40%, 
however, survival of advanced esophageal cancer is poor, with a median survival of 7 to 
8 months. Although there is no standard chemotherapy for advanced esophageal 
cancer, platinum based regimens have been used mostly in fit patients. The addition of 
new cytotoxic agents like paclitaxel and irinotecan seems to lead to higher response 
rates. A number of patients who progress after first line chemotherapy given for 
advanced disease, may still be fit for second line treatment. There is no drug presently 
available with substantial activity in this setting 4.  
 Gefitinib (ZD1839, IRESSATM) is a specific tyrosine kinase inhibitor (TKI) of EGFR 5 
that has been approved in Japan and a number of other counties as single agent 
therapy for patients with refractory NSCLC. The response rate in Caucasian patients is 
10-20%, while another 20-30% of the treated patients show stable disease for at least 2 
months 6. Somatic mutations within the EGFR kinase domain correlate with a dramatic 
clinical response to gefitinib in NSCLC patients 7,8. Moreover, gefitinib-treated NSCLC 
patients with nuclear phospho-Akt tumor staining demonstrated an improved outcome 
9. Conversely, k-ras mutations are associated with primary resistance of NSCLC patients 
to EGFR-TKI therapy 10. In contrast, EGFR, HER2, and phospho-Erk stainings did not 
predict for response of NSCLC patients to gefitinib 11,12. 
The EGFR is a membrane-bound tyrosine kinase receptor that mediates growth and 
survival signals 13. EGFR is activated upon binding of ligand to its extracellular domain, 
resulting in autophosphorylation and activation of downstream signaling molecules, 
such as Ras, Erk, PI3K, and Akt. The EGFR plays a prominent role in tumorigenesis, as it 
promotes growth of cells and is highly expressed and/or mutated in a variety of solid 
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tumor types, including esophageal cancer, NSCLC, and glioma 14. EGFR overexpression 
was observed in 29-92% of esophageal tumors, which was correlated with poor patient 
prognosis and inferior response to therapy 15. 
 In this study we present the results of a phase II study of second-line gefitinib 
monotherapy for patients with advanced esophageal cancer, after failure of 
chemotherapy. We investigated the tumor material of these patients for a number of 
potential biological markers of activity. 
 
Patients and Methods 
 
 This was a phase II study of gefitinib in patients who relapsed after chemotherapy for advanced 
esophageal cancer (1839IL/0059). The primary objectives of this study were to assess tumor response 
according to the RECIST criteria 16; secondary endpoints were to estimate the duration of responses and 
progression-free survival, disease control rate and the tolerability of the treatment. 
 
Patients 
 Entry criterias included: histologically confirmed carcinomas of the esophagus, WHO performance 
status of 2 or less, measurable or evaluable disease. Patients with cancers of the gastroesophageal 
junction were included if more than 50% of the tumor was localized in the esophagus. Patients had to 
have relapsed after one chemotherapy regimen, given at least 4 weeks before, and have white blood cells 
> 4000/mm3 and platelets > 100000/mm3, serum creatinine within 1.5 times the UNL (upper normal limit), 
and transaminases up to 5 times UNL in case of liver metastases. Patients had to be greater than 18 years 
old, and life expectancy was to be 12 weeks or longer. Excluded were patients that received prior 
treatment with an EGFR inhibitor, patients with brain metastases, those with unresolved toxicities from 
prior treatment, other active malignancies in the last 5 years, female patients who were pregnant or 
breast feeding, and patients using concomitant liver enzyme inducing medicines (e.g. phenobarbital, 
phenytoin).  
Patients gave written informed consent and the study was approved by the ethical committees of the 
two institutions that participated in this study. 
 
Treatment 
 Before enrolment patients underwent clinical examination, ECG, full blood counts, chemistries and 
urinalysis, and tumor assessment by CT scans of the chest and abdomen. During treatment, clinical 
examination, full blood counts, and chemistries were repeated every 2 weeks for the first 2 months, 
thereafter every month. Tumor assessment was repeated every 8 weeks. Tumor biopsies were performed 
at start and every 4 weeks whenever feasible. Gefitinib was given at 500 mg/day (two 250 mg tablets at 
each dosing) by oral route without interruption, unless severe toxicity ensued. In case of excessive 
toxicity interruptions were allowed up to 14 days. In case the side effect would not return to lower than 
grade 2, dose reduction to 250 mg/day was allowed. No more than one dose reduction was permitted. 
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Toxicity was assessed according to the NCI CTC grading system. Treatment continued until excessive 
toxicity, progression or patient request. 
 
DNA isolation, PCR, and sequencing 
 Tumor specimens obtained at the time of primary diagnosis or study entry were collected to analyze 
the gene status of EGFR, k-ras, and PIK3CA. Paraffin-embedded tissue sections were macro-dissected and 
total genomic DNA was isolated using QIAamp DNA extraction Kits (Qiagen, Venlo, The Netherlands). 
Nested PCRs were carried out using the isolated DNA as template and external and internal primers as 
previously described 17. Sequencing of PCR products was performed using the BigDyeTM Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA), M13 primers 17 and the ABI PRISMTM 310 
Genetic analyzer (Applied Biosystems). 
 
Immunohistochemical staining 
Tumor slides were deparaffinized, autoclaved in 10 mM citrate buffer (pH 6.0), and incubated with 
EGFR antibody (VUMC), P-Akt (Ser 473) antibody (Cell Signaling, Beverly, MA; #9277), or P-p44/42 Mapk 
(Thr202/Tyr204) antibody (Cell Signaling; #9106) overnight at 4°C. The sections were developed using the 
DAKO EnVisionTM visualization system. At present, there are no validated scoring systems for interpreting 
immununohistochemical staining for EGFR, P-Akt, or P-Erk. We used a system for interpreting EGFR 
staining that was based on scoring HER2 staining 18: 0, none of the tumor cells stained; 1+, the staining of 
the tumor cell membranes was weak and incomplete; 2+, the staining of the tumor cell membranes was 
moderate and complete; 3+, the staining of the tumor cell membranes was strong and complete. 
Interpreting P-Akt and P-Erk staining was based on staining incidence and intensity: 0, none of the tumor 
cells stained; 1+, less than 10% of the tumor cells stained weakly; 2+, more than 10% of the tumor cells 
stained moderately; 3+, more than 25% of the tumor cells stained strongly. Interpretation of 




 Tumor sections were deparaffinized, boiled for 10 minutes in 1 mM EDTA/Tris (pH 9.0), digested with 
0.01% pepsin/0.2 N HCl at 37°C, washed, and dried. Subsequently, the slides were incubated with the 
Zymed POT-light EGFR amplification probe (Zymed Laboratories Inc., San Francisco, CA) for 16-24h at 
37°C after denaturation at 80°C. After blocking with goat anti-serum and incubation with a monoclonal 
anti-digoxin antibody (Clone DI-22; Sigma, Zwijndrecht, The Netherlands), the sections were developed 
using the DAKO EnVisionTM visualization system. Similar to EGFR CISH analysis by Bhargava et al. 19, 
tumors were considered to be CISH+ when >50% of the tumor cells showed tight EGFR clusters or had >4 
EGFR gene copies. Evaluation of the slides was performed independently by two authors, who were 
blinded to the patients' clinical characteristics and all other molecular variables. 
 
Study design and statistical analysis 
 The study was performed as a phase II single agent trial, using a Fleming’s single-stage design. The 
minimum required response rate of interest was set at 5% and the response of clinical interest was set at 
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20%. The required number of patients to be recruited was 38, based on a 90% power. Response rates and 
controlled disease rates were summarized by percentages and their 95% confidence intervals. Survival 
curves were constructed using the Kaplan-Meier method, and differences between the two groups were 
analyzed using the log-rank test. Patients groups were compared with the Spearman’s Rho or Chi-square 
test when appropriate. All statistical analyses were performed using SPSS software (version 11.0.1). *, 




Patient characteristics and treatment outcome 
Thirty-seven patients were screened and enrolled from February 2002 to February 
2004, and 36 were eligible to the study and received at least one dose of gefitinib. One 
patient was found not to be eligible because of poor performance status and 
deteriorating conditions, and did not start treatment. The main patient characteristics 
are summarized in table 1. The majority of patients were male, with good performance 
status, adenocarcinoma and half of patients had prior surgery. 
 Of the 36 patients treated in the study, none had a complete response, one had a 
partial response (2.8%, 95% CI 0.1% - 14.5%), which lasted 3 months, 10 patients had 
stable disease (27.8%) and 17 patients progressed (47.2%). Eight patients (22.2%) were 
considered not evaluable for response, because the first evaluation was not performed 
due to early disease progression (n=2), adverse events (n=2), discontinuation of 
 
Table 1. Patient characteristics. 
Total number of eligible patients 36 
Gender: male / female 25/11 
Mean age (range), years 58 (36-75) 
WHO performance status: 0 / 1 / 2 12/17/7 
Histology 
 Adenocarcinoma 26 (72.2%) 
 SCC 9 (25%) 
 Adenosquamous carcinoma 1 (2.8%) 
Prior chemotherapy 
 Platinum based 34 (94%) 
 5FU based 10 (28%) 
 Partial response 8 (22%) 
Prior surgery 18 (50%) 
Prior radiotherapy 12 (33%) 
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Table 2. Patient characteristics and association with response. 
a Response: PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable 
b SCC, squamous cell carcinoma; ADC, adenocarcinoma; ADSC, adenosquamous carcinoma 
c Smoking history is not known for two patients 
 
gefitinib intake (n=2), or death before the first assessment (n=2). The disease control 
rate (response plus stable disease) was 30.6%. The median time to progression was 59 
days (95% CI, 49 – 80 days). The proportion of patients alive and progression-free at 6 
months was 18.5%. Of 3 patients still alive at the end of the study (6 months after the 
last inclusion), one patient was progression-free with a stable disease and on treatment. 
Median survival time was 164 days (95% CI= 0 to 333 days) and 6 patients (16.7%) were 
alive at one year (Fig. 1). Interestingly, controlled disease was significantly associated 
with being female and SCC histology (Table 2). 
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Figure 1.  Kaplan-Meier curve for overall survival of pretreated esophageal cancer patients treated 
with gefitinib. Survival was calculated from the date of gefitinib therapy initiation to the date of death. 
Median survival time was 164 days (95% CI= 0 to 333 days). 
 
Side effects 
The major reason for treatment discontinuation was disease progression in 29 patients 
(80.6%). Five patients had treatment interruption due to toxicity and 4 patients had a 
dose reduction. The most common gefitinib related side effect was diarrhea (58.3%), 
followed by rash (47.2%). Main side effects are reported in table 3. Severe side effects 
were relatively infrequent, and in general the treatment was well tolerated. No toxic 
death was reported. 
 
Table 3. Most common side effects to gefitinib (n=36) 
 
Toxicity All grades (%) Grade 3-4 (%) 
Diarrhea 21 (58.3) 3 (8.3) 
Rash 17 (47.2) 1 (2.8) 
Dry skin 4 (11.1)  
Erythema  4 (11.1)  
Increased AST 5 (13.9) 1 (2.8) 
Increased ALT 3 (8.3) 1 (2.8) 
Vomiting  3 (8.3) 1 (2.8) 
Nausea 4 (11.1)  
Stomatitis  4 (11.1)  
—   Overall survival
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Figure 2.  EGFR, p-Akt, and p-Erk staining as determined by immunohistochemistry. Panels show 
representative examples of esophageal tumor specimens stained for total EGFR (A, D, G, J), 
phosphorylated (p) Akt (B, E, H, K), and phosphorylated (p) Erk (C, F, I, L). Panels illustrate specimens with 0 
(A-C), 1+ (D-F), 2+ (G-I), and 3+ (J-L) expression levels. All esophageal tumors were positive for p-Akt, 
hence SW1573 NSCLC cells were shown as a control for negative staining (0) of p-Akt (B). 
 
EGFR, k-ras and PIK3CA mutational analysis 
 Esophageal tumors were evaluated for the presence of activating mutations in 
exons 18 to 21 of the EGFR gene 7,8. All of the 26 evaluated esophageal tumors were 
wild type for this region of the EGFR gene. Esophageal tumors were additionally 
screened for activating mutations in the k-ras and PIK3CA genes, which may confer 
resistance to gefitinib. Although no mutations were found in hotspot regions of the 
PIK3CA gene in 24 tumors tested, two out of 23 evaluated tumors (8.7 %) harbored 
point mutations in codon 12 or 13 of the k-ras gene (data not shown). Both patients 
with a k-ras mutation had (early) disease progression upon gefitinib treatment. 
 
Expression of EGFR 
 Among the 24 tumors evaluated for EGFR expression, 15 (62.5%) had low or 
moderate (0/1+/2+) EGFR expression and 9 (37.5%) were highly positive (3+) for EGFR 
(Table 4; Fig. 2). High EGFR expression was significantly associated with SCC histology, 
but not with other clinical parameters (Table 4). The disease control rate was 66.7% for 
patients with high EGFR expressing tumors, which was significantly higher than for 
patients with low to moderate EGFR expressing tumors (Table 5). The time to 
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progression was longer for patients with high EGFR expressing tumors (median 153 
days, 95% CI 36-270 days) than for patients with low or moderate EGFR expressing 
tumor (median 55 days, 95% CI 42-68 days), although this was not statistically 
significant (Fig. 3A). The overall survival for patients with high EGFR expressing tumors 
(median 233 days, 95% CI 110-356 days) was longer compared to that of patients with 
low or moderate EGFR expressing tumors (median 83 days, 95% CI 25-141 days), but 
this was not significantly different (Fig. 3B). 
 
Table 4.  Patient characteristics and association with EGFR, p-Akt, and p-Erk status determined by 
immunohistochemistry. 
 
Expression of p-Akt 
Stainings of esophageal tumor sections for p-Akt were difficult to interpret, as 
particularly adenocarcinomas showed p-Akt staining (1+ to 2+) of surrounding normal 
tissue. However, tumor tissue usually showed strong, nuclear p-Akt staining compared 
to weaker staining of surrounding normal tissue. When considering tissues with tumor-
specific staining only, 13 tumors were evaluable. Of these tumors, 7 were highly positive 
(3+) for p-Akt, and 6 expressed low to moderate (1+/2+) expression of p-Akt (Table 4). 
High p-Akt staining was associated with being male, but not with other patient 
characteristics (Table 4). Patients with low p-Akt expression had better disease control 
(Table 5) and longer progression free survival compared to patients with high p-Akt 
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status (median 153 days, 95% CI: 0-316 days vs. median 49 days, 95% CI: 37-61 days) 
(Fig. 3C). However, overall median survival was not significantly different on the basis of 
p-Akt status (191 days, 95% CI: 0-388 days vs. 133 days, 95% CI: 87-179 days) (Fig. 3D). 
 
Expression of p-Erk 
 Of the 22 tumors that were stained for p-Erk, 14 (63.6%) had negative (0/1+) p-Erk 
expression and 8 tumors (36.4%) showed positive (2+/3+) p-Erk expression (Table 3; 
Figure 3E, F). High Erk phosphorylation was observed more frequently in 
adenocarcinomas and in patients that had no prior radiotherapy (Table 3). Disease 
control rates, the median time to progression (56 days, 95% CI: 41-70 days vs. 62 days, 
95% CI: 27-97 days), and the median survival time (115 days, 95% CI: 82-148 days vs. 234 
days, 95% CI: 0-535 days) were similar among patients whose tumors differed on the 
basis of p-Erk status (Table 4, Fig. 3E, F).  
 
EGFR gene copy number 
 EGFR gene copy numbers of 16 tumors were evaluated by CISH. Two tumors 
(12.5%) were considered CISH+ (data not shown), among which the tumor from the 
patient with a partial response and a patient with disease progression upon gefitinib 
treatment. Similar to recent findings of Hanawa et al. 20, the two CISH+ cases showed 
high (3+) EGFR protein expression and SCC histology. 
 
Table 5.  Response of gefitinib therapy in patients with advanced esophageal cancer according to 
total EGFR, phosphorylated Akt, and phosphorylated Erk expression. 
 
Tumor status 
Total No. of evaluated 
patients (%) 
No. of partial responses and 
stable disease (%) P 
Total 36 11 (30.6)  
EGFR Total 24 7 (29.2)  
 0/1+/2+ 15 1 (6.7) 
 3+ 9 6 (66.7) 
.002** 
p-Akt Total 13 4 (30.7)  
 1+/2+ 6 4 (66.7) 
 3+ 7 0 (0) 
.009** 
p-Erk Total 22 7 (31.8)  
 0/1+ 11 4 (36.4) 







Figure 3.  Kaplan-Meier curves for time to disease progression (A, C, E) and survival (B, D, F) according 
to protein expression levels of EGFR (A-B), phosphorylated (p-) Akt (C-D), and phosphorylated (p-) Erk (E-
F). Time to disease progression was calculated from the date of initiation of gefitinib treatment to the 
date of detection of progressive disease. Survival was calculated from the date of therapy initiation to the 
date of death. Statistical significance of differences between groups was evaluated with the log-rank test. 
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 Gefitinib given at 500 mg/day in second-line treatment of advanced esophageal 
cancer, failing after chemotherapy induced one partial response. Although this 
response rate (2.8%) is disappointing, 30.6% of patients demonstrated controlled 
disease. These results suggest that gefitinib as monotherapy is less effective than 
historical controls which, with cytotoxic chemotherapy regimes have recorded 
response rates of 12-30% for patients who have received 2nd line therapy, with 
progression free survivals of approximately 3.5 months 21,22 in comparison to a 
progression free survival of 2 months in this study. The safety profile of gefitinib given 
at 500 mg is similar to other studies with this agent and demonstrates that the drug is 
well tolerated. The overall adverse events profile was, as expected, predominated by 
gastro-intestinal and skin related events. 
Although the clinical results were disappointing, we attempted to identify the 
patients that had benefit from gefitinib treatment, in particular the patients who had a 
response or stable disease (Table 6). 
 
Table 6.   Characteristics of non-progressive esophageal cancer patients upon gefitinib therapy. 
a Response: PR, partial response; SD, stable disease 
b SCC, SCC; ADC, adenocarcinoma; ADSC, adenosquamous carcinoma 
c EGFR, PIK3CA, and k-Ras mutational status was determined by direct DNA sequencing. WT, wild type. 
d EGFR and phosphorylation status of Akt and Erk were determined by immunohistochemistry. For 
definition of degree of expression see materials and methods. NE, Not Evaluable 
 
Analogous to studies evaluating gefitinib in NSCLC 6, being female predicted for a 
better patient outcome in this study. In contrast to lung cancer studies, we found that 
SCC histology was significantly associated with a better patient outcome. Our results 
are consistent with a large phase II trial using gefitinib in SCCs of the head and neck 












0601.04 SD M 68 SCC 2 Yes Yes WT WT WT  3+ 2+ 0 
0601.05 SD M 52 ADC 1 Yes No WT WT WT  3+ NE 3+ 
0601.15 SD M 63 ADC 2 Yes No WT WT WT  NE NE NE 
0601.21 SD F 58 ADC 0 Yes No WT WT WT  2+ NE 3+ 
0613.01 SD F 58 SCC 0 Yes No WT NE NE  3+ 1+ 1+ 
0613.02 PR F 69 SCC 0 Yes No WT WT WT  3+ 2+ 0 
0613.05 SD F 51 ADC 0 No No NE NE NE  NE NE NE 
0613.07 SD M 60 SCC 0 No No NE NE NE  NE NE NE 
0613.08 SD F 62 SCC 2 Yes Yes WT WT WT  3+ 2+ 0 
0613.09 SD F 52 ADSC 0 Yes No NE NE NE  NE NE NE 




(n=47), in which a response rate of 10.4 % was reported, while 53% of patients 
experienced stable disease 23. These numbers are similar to the response and stable 
disease rates of 12.5% and 50%, respectively, within the group of patients with SCC 
histology (n=8) in the study presented here. Therefore, the fact that the majority of the 
patients were male and had adenocarcinoma histology may have decreased the overall 
response rate in this study. Thus, selection of patients on the basis of SCC histology 
might have improved the outcome. 
In addition to clinical parameters, we investigated several potential biological 
markers of gefitinib activity. Given the fact that only a part of the tumors were evaluable 
for biomarker-analysis, the results presented in this study are unfortunately not 
conclusive. The finding that EGFR kinase domain mutations were not detected in 
esophageal tumors may be due to the low frequency of EGFR mutations detected in 
tumors other than NSCLC 24. In line with our results, no EGFR mutations were reported 
in a recent study evaluating 40 esophageal SCCs 20. On the other hand, we did not 
observe such dramatic clinical responses upon treatment with gefitinib in this study as 
those that have been described for EGFR mutant NSCLC patients treated with EGFR-TKIs 
7,8. However, patients with high EGFR expression experienced significantly better-
controlled disease and demonstrated a trend towards improved time to progression 
and overall survival while on treatment. Our data suggest that patients with high EGFR 
expression may have a better prognosis when treated with EGFR-TKIs, as high EGFR 
expression has been shown to be a bad prognostic factor for esophageal cancer 
patients 25,26. As esophageal cancers overexpress EGFR in 29-92% of cases 15, it is 
conceivable that a higher response or disease control rate might be achieved if patients 
were selected on the basis of high EGFR expression. 
 Two out of four cases with high EGFR expression were also CISH+ (data not shown). 
This suggests that EGFR overexpression is caused by increased EGFR gene copy number 
in just a fraction of esophageal tumors, like Hanawa et al. reported recently 20. Our data 
further suggest that analysis of EGFR expression by immunohistochemistry is more 
effective to predict gefitinib efficacy in esophageal cancer patients than EGFR gene 
copy number, in contrast to NSCLC 11,12,27. However, direct comparisons are difficult 
between the immunohistochemical data of the different studies because of differences 
in antibodies used and interpretation of the results. The introduction of a standardized 
system for scoring EGFR immunohistochemical stainings is needed. 
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 EGFR-independent activity of the downstream Ras/Erk and PI3K/Akt pathways 
confers resistance of tumor cells to gefitinib treatment 28. Similar to NSCLCs 10,17, the 
presence of k-ras mutations in esophageal tumors may be a factor of resistance to 
gefitinib, as two patients with k-ras mutant tumors were progressive upon gefitinib 
therapy. However, phosphorylation of Erk, downstream of k-ras 29, was not elevated in 
tumors with k-ras mutations and p-Erk status was not predictive for outcome to 
gefitinib treatment. No mutations were detected in the PIK3CA gene in 24 esophageal 
tumors. PIK3CA mutations are relatively frequent in colorectal, breast and ovarian 
tumors, but less frequent in other tumor types 30,31. Low p-Akt staining is associated 
with better disease control and longer progression-free survival in the small group of 
patients evaluated. However, p-Akt status, downstream of PI3K 32, will not be a good 
predictive factor for gefitinib therapy in esophageal cancer, because of the difficult 
evaluation of phosphorylated Akt levels. 
In conclusion, gefitinib treatment of unselected patients with advanced, pretreated 
esophageal cancer has modest activity. However, being female, high EGFR expression 
levels, and SCC histology are associated with better patient outcome. The selection of 
esophageal cancer patients for future studies with EGFR-TKIs based on the level of EGFR 
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Kahalalide F (KF) is a novel marine-derived antitumor agent that is currently 
undergoing phase II clinical trials. The mechanism of action of KF is not well 
understood. In line with previous reports, we show that KF caused rapid and 
potent cytotoxicity in the breast cancer cell lines SKBR3 and BT474, 
characterized by cytoplasmic swelling and DNA clumping. Several markers of 
caspase-dependent apoptosis, such as phosphatidyl-serine externalization, 
cytochrome C release, and caspase-3 and PARP cleavage were negative after KF 
exposure. Inhibitors of caspases or cathepsins failed to protect against KF-
cytotoxicity. Altogether, these data indicate that KF-induced cell death is a 
necrosis-like process. The sensitivity to KF in a panel of human tumor cell lines 
derived from breast (SKBR3, BT474, MCF7), vulval (A431), non-small cell lung 
(H460, A549, SW1573, H292), and hepatic (Skhep1, HepG2, Hep3B) carcinoma, 
positively correlated with ErbB3 (HER3) protein levels. A KF-resistant subline of 
colon carcinoma cells, HT29/KF, expressed significantly reduced levels of all ErbB 
receptors, but short term KF exposure of sensitive cell lines such as SKBR3 
selectively induced downregulation of ErbB3. Conversely, stable transfection of 
an ErbB3-expressing plasmid increased the KF sensitivity of H460 cells, the most 
resistant cell line in our panel. Finally, we found that KF efficiently inhibited the 
PI3K-Akt signaling pathway in sensitive cell lines and that ectopic expression of 
a constitutively active Akt mutant reduced KF cytotoxicity in this cell line. In 
summary, our results identify ErbB3 and the downstream PI3K-Akt pathway as 
important determinants of the cytotoxic activity of KF in vitro. 




Kahalalide F (KF) is a novel antitumor agent that was originally isolated from 
the Hawaiian marine mollusk Elysia rufescens 1,2. KF has high cytotoxic activity 
against cell lines and tumor specimens derived from various human solid 
tumors, including prostate, breast, NSCL, ovarian, and colon carcinomas 3-7. 
Moreover, KF has shown antitumor activity against human prostate cancer 
xenografts in mouse models 3. In contrast, non-tumoral cell lines were 5-40 
times less sensitive to KF 8 and bone marrow progenitors were not affected 
when treated with supra-pharmacological concentrations of KF 9. In a phase I 
clinical trial in solid tumors antitumor activity has been noted in patients 
harboring hepatoma, melanoma, and breast and pancreatic carcinoma 10. 
Currently, the activity of KF is being investigated in phase II clinical trials in 
patients with melanoma, hepatic carcinoma, an NSCLC 11. 
The molecular mechanism of action of KF is largely unknown. Lysosomes 
appear to be an intracellular target of KF, as human cervical tumor cells and 
monkey fibroblasts treated with KF formed large vacuoles and became 
dramatically swollen due to changes in lysosomal membranes 12. Consistently, a 
recent report demonstrated the loss of lysosomal integrity and the induction of 
severe cytoplasmic swelling and vacuolization in breast and prostate cancer 
cells 13. In the latter study, confocal laser and electron microscopy revealed that 
KF also induces damage of mitochondria, endoplasmatic reticulum, and the 
plasma membrane. In contrast, the nuclear membrane was preserved and no 
DNA damage was detected, although the cell nucleus showed irregular 
clumping of chromatin. Ectopic overexpression of the multidrug resistance 
protein MDR1, inhibition of protein synthesis, or inhibition of caspase-
dependent apoptosis did not significantly protect against KF cytotoxicity 14. 
Inhibition of ErbB signaling has been suggested to be part of the mechanism 
of KF action 4,15, although ectopic overexpression of ErbB2 did not protect 
against KF-induced cell death 16. Here we show that KF-induced cytotoxicity 
does not involve caspase-mediated apoptosis, but is a necrosis-like cell death 
process. KF-induced cell death was also independent from the activity of the 
lysosomal proteases cathepsin B and D. The sensitivity to KF in a panel of cell 




hepatic carcinoma, significantly correlated with protein expression levels of the 
ErbB3 receptor. We show that KF exposure induced downregulation of ErbB3, 
while ectopic expression of ErbB3 increased the KF sensitivity of a resistant cell 
line. Finally, we found that KF efficiently inhibited the PI3K-Akt signaling 
pathway in sensitive cell lines, and that ectopic expression of a constitutively 
active Akt mutant reduced KF cytotoxicity. Altogether, our data identify ErbB3 
and Akt as major determinants of the cytotoxic activity of KF in vitro. 
 
Materials and Methods 
 
Chemicals 
KF (1-Oxa-4,7,10,13,16-pentaazacyclononadecane, cyclic peptide derivative) is 
manufactured by Pharmamar (Madrid, Spain) and was provided as a pure substance and diluted 
in dimethyl sulfoxide (DMSO): ethanol (1:1; v/v). Stock solutions of zVAD-fmk (Enzyme Systems 
Products, Livermore, CA), calpeptin (Calbiochem, Darmstadt, Germany), CA-074 Me (Peptides 
International, Osaka, Japan), zFA-fmk (Enzyme Systems Products), pepstatin A (Sigma Chemicals, 
St. Louis, MO), and LY294002 (Cell Signaling Technology) were made in DMSO. 
 
Cell culture and KF selection 
SKBR3, BT474, MCF7 (breast carcinoma), A431 (vulval carcinoma), NCI-H460 (H460), A549, 
SW1573, NCI-H292 (H292) (NSCLC), SKhep1, HepG2, Hep3B (hepatic carcinoma), and HT29 (colon 
carcinoma) cell lines were grown at 37° C and 5% CO2 in Dulbecco's modified Eagle's medium or 
RPMI-1640 (BioWhittaker) supplemented with 10% (v/v) fetal calf serum (Life Technologies, 
Breda, The Netherlands), 100 units/ml penicillin and 100 µg/ml streptomycin (Gibco BRL). Cells 
from exponentially growing cultures were used in all experiments. The KF-resistant HT29 cell line 
(HT29/KF) (supplied by Dr. Lola Garcia Grávalos, Pharmamar, Madrid, Spain) was obtained by 
treating parental HT29 cells with increasing concentrations of KF, from 0.15 µM KF to 1.3 µM KF, 
in which the cells grew well after 20 weeks of selection. 
 
Flow cytometry 
Cells were plated at 40-60% confluency in 6- or 12-well plates. The following day, the 
medium was replaced with medium containing the drug(s), as indicated. Cells were treated for 
various times with 1 µM KF, unless otherwise indicated. Protease inhibitors were diluted in 
medium at final concentrations of 50 µM (zVAD-fmk), 100 µM (calpeptin, CA-074 Me, pepstatin 
A) or 200 µM (zFA-fmk), and added to the cells 1 hr prior to addition of KF. Cell cycle analysis and 
apoptosis measurement were performed as previously described 17. Briefly, the cell cycle 
distribution was determined by propidium iodide (PI) staining of cells, which were resuspended 
in Nicoletti buffer 18 and analyzed by flow cytometry. The extent of cell death was determined by 
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the analysis of hypodiploid DNA using PI-staining, or by annexin V-FITC and 7-amino-
actinomycin D (7-AAD) double staining according to the manufacturer’s protocol (Nexins 
Research, Kattendijk, The Netherlands). All analyses were performed on a FACScalibur 
instrument using the CellQuest software package (Becton Dickinson, Mount View, CA).  
 
Western Blotting 
Whole cell lysates were denatured in sample buffer containing SDS and equal amounts of 
total protein were separated on 8-15 % SDS-poly-acrylamide gels and transferred to 
nitrocellulose membranes. After blocking with 5 % nonfat dry milk, the membranes were 
incubated O/N at 4° C with the first antibodies as indicated. The next day, the membranes were 
incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies, and 
detection was performed using enhanced chemiluminescence reagent (Amersham). The 
antibodies used are: anti-caspase-3, anti-phospho-EGFR (Tyr1068), anti-Erk, anti-phospho-Erk, 
anti-Akt, anti-phospho-Akt (Ser473), anti-phospho-MDM2, anti-phospho-GSK-3β (all from Cell 
Signaling Technology), anti-PARP (Roche), anti-EGFR (Ab-12, Neomarkers), anti-c-ErbB2 (C18, 
Santa Cruz), anti-phospho-c-ErbB2 (Tyr1248; Neomarkers), anti-c-ErbB3 (Ab-2, Neomarkers), anti-
c-ErbB-4 (Ab-2, Neomarkers). Protein expression levels were quantified using Biorad software 
and normalized with β-actin expression levels. 
 
MTT assays 
5 x 103 cells were plated into flat bottom 96-well plates (Costar, Corning, NY). After 24 h, 
various concentrations of KF were added and the cells were incubated for an additional 72 h.  
Subsequently, 10% (v/v) of a solution of 5 mg/ml 3-(4,5)-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma) was added to each well and incubated for 3 h at 37o 
C. Plates were centrifuged for 5 min at 1200 rpm and the medium was carefully discarded. The 
formed formazan crystals were dissolved in 100 µl DMSO and absorbance was determined at 
540 nm using a Spectra Fluorimeter (Tecan, Salzburg, Austria). Absorbance values were 
expressed as the percentage of the untreated controls to calculate the concentration of KF 
resulting in 50% growth inhibition (IC50). 
 
Immunocytochemistry, fluorescence microscopy analysis and quantification of subcellular 
distribution 
Cells growing onto glass coverslips were fixed with 3.7% formaldehyde in PBS for 30 min, 
washed with PBS, permeabilized with 0.2% Triton in PBS for 10 min, and washed with PBS again. 
Following a blocking step with 3% bovine serum albumin in PBS for 1 h, primary antibodies 
against p27kip1 (BD Biosciences) or cytochrome c were diluted in blocking solution and applied 
for 1 h. After washing with PBS, cells were incubated with fluorescein isothiocyanate (FITC)- 
(Sigma) or Alexafluor Red- (Molecular Probes, Eugene, OR) conjugated secondary antibodies for 
1 h. Finally, the coverslips were rinsed three times with PBS and mounted onto microscope slides 




counterstain the nuclei. The immunostaining procedure was carried out at room temperature. 
Fluorescence microscopy analysis was carried out using an inverted Leica DMIRB/E fluorescence 
microscope (Leica Heidelberg, Heidelberg, Germany). Images were collected using the Q500MC 
Quantimet software V01.01 (Leica Cambridge, Cambridge, U.K.). To quantify the subcellular 




The mammalian expression vectors pBABE-ErbB3 19 and pSG5-gagPKB 20 were generously 
provided by Dr. N. Hynes (Friedrich Miescher Institute, Basel, Switzerland) and Dr. P. Coffer 
(University Medical Center, Utrecht, The Netherlands), respectively. Cells were seeded in 6- or 12-
well trays, and transfected with 0.5-2 µg of plasmid DNA using the FuGene6 transfection reagent 
(Roche Molecular Biochemicals), according to the manufacturer’s protocol. For transient 
transfection experiments, cells were transfected with the YFP-expression plasmid pEYFP-C1 
(Clontech, Palo Alto, CA, U.S.A.) alone or together with the pSG5-gagPKB vector. Using YFP 
expression as a marker of transfection, we determined the percentage of transfected cells that 
detached after treatment with KF. Expression of gag-PKB was confirmed by Western blotting in a 
parallel sample. Finally, to make stable ErbB3 expressing cells, H460 cells were transfected with 
5-10 µg pBABE-ErbB3 cDNA or empty vector control vectors, using Superfect reagent (Gibco 
BRL) according to the manufacturer’s protocol. Transfected cells were selected in puromycin-
containing medium and the pooled population was used. 
 
Statistics 
Correlation coefficients (r) and accompanying P-values were calculated using SPSS software. 
Quantitative experiments were analyzed by the Student’s t-test and p-values resulted from the 




KF-induced cytotoxicity is mediated through a necrosis-like cell death 
process 
To investigate if KF induces the activation of caspase-dependent apoptosis, 
we examined several apoptotic markers after treatment with KF. First, cell cycle 
analysis revealed that KF induces a hypodiploid cell population in SKBR3 and 
BT474 cells, starting after 16 to 24 h exposure to KF and increasing to almost 
100% after 72 h (Figure 1A). Flow cytometric analysis after 7-AAD/Annexin-V 
double staining demonstrated that KF caused a rapid disruption of the cell 
membrane, as visualized by the increase of 7-AAD staining (Figure 1B). However, 







Figure 1.  KF induces necrosis-like cell death. A, flow cytometry analysis of the DNA content of 
BT474 and SKBR3 cells stained with propidium iodide (PI) after exposure to KF (1 µM) for 
different times. Representative examples of the cell cycle distribution of SKBR3 cells untreated or 
treated for 24 or 48 h with KF are shown (left panels). The amount of cells with hypodiploid DNA 
content (M1) was measured and presented as percentage of total cell population (right panel). B, 
KF-treated SKBR3 cells (1 µM for 4h) were double-stained with annexin-V/7-AAD and analyzed by 
flow cytometry. Gate-settings distinguish between living (lower left), necrotic (upper left), early 
apoptotic (lower right) and late apoptotic (upper right) cells. C, Cytochrome C is not released 
from mitochondria in cells affected by KF treatment. Representative examples of SKBR3 cells 
stained for Hoechst (left panels) and cytochrome C (Cyt C) (right panels) incubated without (UT) 
or with KF (1 µM) for 2 h. The arrow in the bottom panels indicates a cell with clumped DNA but 
no cytochrome C release. D, Effect of KF on caspase-3 and PARP-cleavage. SKBR3 cells were 
incubated for the indicated period of time with KF and effects on caspase-3 and PARP was 
analysed by Western blotting. As a control, cells were treated with cisplatin (10 µM) for 24 h (lane 
6). The membranes were stripped and reprobed with anti-β-actin to verify equal protein loading. 
E, No effect of caspase or cathepsin B or D inhibition on KF-induced sub-G1 population. SKBR3 
cells were pretreated with the pan-caspase inhibitor zVAD-fmk (50 µM), the cathepsin B 
inhibitors zFA-fmk (ZFA) or CA-074 (CA), or the cathepsin D inhibitor pepstatin A (pepA) for 1 h 
before addition of KF (1 µM). The sub-G1 population was measured after 24 h as in A. Values 





























































Annexin-V staining remained negative after treatment (Figure 1B), indicating 
that KF does not induce the externalization of phosphatidyl-serine (PS), which is 
characteristic of apoptotic cell death. KF-treatment resulted in DNA clumping, 
but cytochrome C remained within mitochondria even in cells clearly affected 
by KF-treatment (Figure 1C, indicated by the arrow). The sensitivity to KF of A549 
cells overexpressing the anti-apoptotic protein Bcl-2 was similar to that of non-
transfected cells (data not shown), further indicating that apoptosis was not 
involved in the action of KF. Neither caspase-3 nor PARP were cleaved after up 
to 24 h exposure to KF (Figure 1D; upper panel), and co-treatment with the 
broad caspase inhibitor zVAD-fmk did not prevent the hypodiploid cell 
population induced by KF (Figure 1E). PARP was degraded after 16 h exposure 
to KF, but the 89 kD caspase-dependent cleavage product that appeared in 
control cells treated with cisplatin, was not observed (Figure 1D; middle panel). 
This suggests that other proteases were involved in KF-induced degradation of 
PARP. 
Previous reports that KF induces the loss of lysosomal integrity 21,22 and that 
PARP can be degraded by lysosomal cathepsins during necrosis 23 raised the 
possibility that the observed KF-induced PARP degradation could be mediated 
by these proteases, and that cathepsins might be involved in the action of KF. To 
investigate this possiblity, cells were co-treated with zFA-fmk or CA-074-ME, 
which are specific inhibitors of cathepsin B, or with the cathepsin D inhibitor 
pepstatin A. As shown in Figure 1E, inhibition of cathepsin B or D failed to 
protect from the KF-induced sub-G1 population, demonstrating that the activity 
of cathepsin B or D is not required for KF-mediated cytotoxicity. Taken together, 
these data demonstrate that KF does not activate caspase-dependent apoptosis, 
but causes cell death that resembles necrosis. 
 
ErbB3 expression levels correlate with KF sensitivity 
Using normal human skin fibroblasts, we confirmed previous reports 24,25 
that non-tumoral cells have 5- to 40-times higher IC50 values for KF compared to 
sensitive tumor cells (data not shown). Malignant cells commonly possess over-
activated signal transduction cascades that provide potential selective targets of 
antitumor drugs 26. Since KF inhibits the EGFR and ErbB2 receptors and 
downregulates TGFα gene expression 4,27, and high expression of the ErbB 
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family of receptor tyrosine kinases is prevalent in tumor cells 28, we investigated 
if protein expression levels of ErbB receptors (ErbB1-4) correlate with the 
sensitivity to KF in a panel of tumor cell lines with variable expression of each 
receptor. The IC50 concentrations for KF, as measured in MTT assays, ranged 
from 0.1 µM to 7 µM within the panel of cell lines (Figure 2A). The sensitivity of 
the cell lines to KF did not correlate with their EGFR (ErbB1), ErbB2, or ErbB4 
protein expression levels (Figure 2B). However, ErbB3 levels showed a significant 
inverse correlation (r= -0.61, P= 0.0428) with IC50 concentrations of KF (Figure 
2B).  
 
Figure 2.  ErbB3 protein expression levels correlate with KF sensitivity. Correlation of KF 
sensitivity with expression of the ErbB family of kinases. A, Basal ErbB expression levels were 
evaluated by western blotting. IC50 values of KF represent the mean and SD of at least three 
independent MTT assays (see materials and methods). B, The ErbB protein expression levels 
shown in fig A were quantified using Quantity One (Biorad) software, normalized with β-actin 
expression levels, and plotted against the mean IC50 concentrations of KF. Pearson’s correlation 
coefficients (r) and P-values were calculated using SPSS software. 
 
KF induces downregulation of ErbB3 protein 
Western blot analysis was carried out to investigate potential differences in 
the expression levels of ErbB receptors in the KF-sensitive HT29 colon carcinoma 
cell line compared to a KF-resistant sub-line (HT29/KF) generated by long term 
exposure to increasing concentrations of the drug, and was capable of growing 
in the presence of 1.3 µM KF (see Materials and Methods). The expression of all 
four ErbB receptors was downregulated in the KF-resistant sub-line compared to 
the parental cell line (Figure 3A). In contrast to the general down-regulation of 























































































































































with KF resulted in the selective downregulation of ErbB3 in sensitive, high 
ErbB3-expressing SKBR3 cells (Figure 3B). 
 
 
Figure 3.  KF induces downregulation of ErbB3 protein. Western blot analysis of protein 
expression levels of ErbB receptors in A, HT29 wild-type (HT29/wt) and KF-resistant HT29 
(HT29/KF) cells that were exposed to KF for a long period of time, and in B, SKBR3 cells treated 
with KF (1 µM) for a short period of time (4 h). The membranes were stripped and reprobed with 
anti-β-actin to verify equal protein loading. 
 
Ectopic ErbB3 expression increases the sensitivity of H460 cells to KF 
To investigate if ectopic ErbB3 expression affects the sensitivity of low ErbB3 
expressing cells to KF treatment, H460 cells were transiently co-transfected with 
cDNA, encoding ErbB3 29 and YFP as a marker of transfection. In comparison to 
control cells co-transfected with an empty vector and YFP, an increased 
percentage of YFP-positive, detached cells was noted in ErbB3 co-transfected 
cells upon KF treatment (data not shown). Next, H460 cells were stably 
transfected with an ErbB3-encoding cDNA. These cells showed increases of 
bands of about 125 and 30 kD, detected with an ErbB3-specific antibody, while 
no induction of full length ErbB3 was observed (Figure 4A, the different isoforms 
are indicated by arrows). Treatment of the H460-pBABE-ErbB3 cells with 2 µM KF 
resulted in decreased expression of the ErbB3-related 125 and 30 kD proteins 
(Figure 4A), similar to previously demonstrated KF-mediated depletion of full 
length ErbB3. In line with the results in transient transfected cells, a higher 
fraction of the H460-pBABE-ErbB3 cell line exhibited morphological signs of KF-
induced cell death compared to control cells transfected with an empty vector 
(Figure 4B). Moreover, H460-pBABE-ErbB3 cells showed a modest but significant 
(p=0.026) reduction of the IC50 concentration of KF compared to empty vector-
transfected cells (Figure 4C). Altogether, the results suggest that ectopic ErbB3 
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Figure 4.  Ectopic ErbB3 expression increases the sensitivity of H460 cells to KF. A, ErbB3 
protein expression was analysed by Western blotting on total cell lysates of H460 cells that were 
stably transfected with the empty pBABE vector or the pBABE-ErbB3 vector. Effect of KF 
treatment on ErbB3 expression was analyzed on cells treated with 1 or 2 µM KF for 4 h. A total 
cell lysate of H292 cells was included as a positive control. The arrows indicate the full length 
ErbB3 of 185 kD and truncated ErbB3 isoforms of about 125, 60 and 30 kD. Note the decrease of 
these proteins after KF treatment. B, Phase contrast pictures of H460 cells stably expressing the 
empty pBABE vector or the pBABE-ErbB3 vector, exposed to 0, 1, or 2 µM of KF for 4 h. The 
arrows indicate cells that were visually affected by KF treatment. C, H460.ErbB3 cells are more 
sensitive for KF treatment than H460.pBABE cells. Growth inhibition induced by various 
concentrations of KF was determined in MTT assays at 72 h. The percentage of survival was 
expressed as the percentage of the untreated controls. Mean, SD, and IC50 concentrations are 
shown from two independent experiments (*, P ≤ 0.05, empty vector vs ErbB3, Student’s t test). 
 
KF depletes ErbB3 and inhibits Akt in KF-sensitive cells 
When a panel of other tumor cell lines was analyzed, we observed that KF 
induced ErbB3-downregulation specifically in sensitive cell lines (Figure 5A). All 
ErbB receptors couple to two major signaling cascades, the MAPK pathway 
involving Ras/Erk, and the PI3K/Akt cascade 30, but ErbB3 is the most efficient 
activator of PI3K 31. Both kinase pathways are involved in the regulation of cell 
proliferation and survival, and are often overactivated in tumor cells 32. 
Phosphorylated or total levels of Erk were not affected by exposure of the 
sensitive SKBR3 cells to KF up to 24 h (Figure 5B). In contrast, phosphorylated 





















































SKBR3 cells with the maximal effect reached after 2 h, which was sustained up to 
at least 24 h (Figure 5B). When the complete panel of cell lines was analyzed, we 
found a decrease of Akt phosphorylation only in those cell lines in which KF 
provoked downregulation of ErbB3 (Figure 5A), suggesting that KF-mediated 
Akt inhibition was due to ErbB3 depletion. In contrast, like ErbB3 expression, Akt 
phosphorylation remained largely unaffected in the KF-resistant cell lines, 
including the acquired resistant subline HT29/KF (Figure 5A). Interestingly, the 
basal levels of phosphorylated Akt were increased in the HT29/KF cell line 
compared to its parental cell line (Figure 5A). 
In a titration experiment in SKBR3 cells, the decrease of phosphorylated Akt 
started at concentrations of 0.25 µM, having the largest effect at 1 µM (Figure 
5C). Consistent with inhibition of Akt activity, the phosphorylation of the Akt 
substrates MDM2 as well as GSK-3β decreased in cells exposed to KF (Figure 5C). 
As an additional marker for Akt activity, the nuclear/cytoplasmic localization of 
p27kip1 was evaluated by immunofluorescence. Nuclear p27kip1 inhibits 
cyclin/CDK complexes resulting in an arrest of cells in the G1 phase of the cell 
cycle 33,34. Phosphorylation of p27kip1 by Akt results in the confinement of p27kip1 
in the cytoplasm, thus stimulating cell cycle progression 35-37. Treatment with KF 
induced redistribution of p27kip1 from the cytosol to the nucleus to a similar 
extent as the selective PI3K inhibitor LY294002, included as a control, further 
demonstrating that Akt activity was inhibited (Figure 5D).  
Cells treated with KF exhibited extensive cytoplasmic swelling cells and 
rapidly detached from the bottom of the tissue culture tray. After treatment with 
KF for 1 h, detached cells were separately harvested from attached cells. 
Downregulation of ErbB3 and inhibition of Akt was only observed in detached 
cells (Figure 5E), indicating that these events coincide with KF-induced 
cytotoxicity. 
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Figure 5.  KF depletes ErbB3 and inhibits Akt in sensitive cells. A, The indicated cell lines were 
left untreated (UT) or exposed to KF (1 µM) for 4 h, and ErbB3 and p (phosphorylated)-Akt 
expression levels were analyzed by Western blotting. The membrane was stripped and reprobed 
with anti-β-actin to verify equal protein loading. B, SKBR3 cells were exposed to KF (1 µM) for 
different times and ErbB3 and total and phosphorylated (p) Erk and Akt were analysed by 
Western blotting. Protein expression levels of ErbB3, p-Akt, and p-Erk were quantified, 
normalized with β-actin, and calculated as percentage of untreated cells. C, SKBR3 cells were 
exposed to different concentrations of KF as indicated, and phosphorylated (p) Akt, mdm2, and 
GSK-3β were analysed by Western blotting. The concentrations of KF resulting in 50% inhibition 
of protein expression (IC50) were calculated after quantification of the Western blots. The lower 
panel shows the quantified and normalized protein expression levels of p-Akt, p-MDM2 and p-
GSK3β plotted against the KF concentration. The graph also shows the survival of SKBR3 cells 
after 72 h treatment plotted against the KF concentration as measured in MTT assays (see 
materials and methods). D, Representative examples of SKBR3 cells incubated without (UT) or 
with KF (1 µM) for 4 h and stained for p27kip1 and Hoechst. The proportion of cells showing 
predominantly nuclear localization of p27kip1, or predominant cytoplasmic p27kip1 localization is 
shown in the bottom panel, including of cells that were treated with the PI3K inhibitor 
LY294002, used as a control. The proportion of cells that had both nuclear and cytoplasmic 
p27kip1 localization is not shown. Values represent the mean and SD by counting at least 200 
cells/treatment in two independent experiments (*, P ≤ 0.05; **, P ≤ 0.01, untreated vs treated, 
Student’s t test). E, SKBR3 cells were exposed for 1 h with KF (1 µM) and the attached and 
detached cell populations were separately harvested and analyzed for ErbB3 and 
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Constitutive activation of Akt protects SKBR3 cells from KF-induced 
cytotoxicity 
KF-mediated Akt dephosphorylation requires the activity of protein 
phosphatases PP2A and/or PP1, as pre-treatment with the phosphatase 
inhibitor okadaic acid (OA) prevented KF-induced Akt dephosphorylation (data 
not shown). However, OA failed to protect against KF-induced cytotoxicity (data 
not shown), probably due to additional toxic effects of PP1 and PP2A inhibition. 
Hence, as another approach to prevent KF-induced inactivation of Akt, cells 
were transfected with a plasmid encoding for gag-PKB, a constitutively active 
mutant of Akt 38.  A smaller number of cells that were transiently co-transfected 
with gag-PKB and YFP exhibited morphological signs of KF-induced cell death 
compared to cells transfected with YFP alone (Figure 6A). As shown in Figure 6B, 
co-transfection with gag-PKB significantly reduced the percentage of YFP-
positive detached cells upon KF treatment, indicating that constitutively active 
Akt protects against KF-cytotoxicity. 
 
Figure 6.  Constitutive activation of Akt protects SKBR3 cells from KF-induced cytotoxicity.  
A, Phase contrast pictures of cells transfected with YFP alone (YFP) or YFP and gag-PKB 
(YFP+gag-PKB), which were left untreated or exposed to KF (1 µM) for 4 or 24 h. B, Fraction of 
YFP-positive cells that had detached from the bottom of the tissue culture tray after exposure to 
KF (1 µM) for 4 or 24 h. Mean and SD are shown from two independent assays by counting at 































In the study presented here, we have investigated the molecular mechanism 
of action of the novel marine ant-cancer compound KF, which is currently being 
investigated in phase II clinical trials. In line with other studies 39,40, we observed 
rapid and potent cytotoxic activity against ErbB2-overexpressing breast cancer 
cell lines, which was associated with the induction of a hypodiploid cell 
population, dramatic cytoplasmic swelling, and permeabilization of the plasma 
and lysosomal membranes. The cell death induced by KF cannot be classified as 
apoptosis, as several apoptotic markers were negative after KF exposure, and 
molecular and chemical inhibitors of caspase-dependent cell death failed to 
protect against KF. In addition to caspase-mediated apoptosis, cells can activate 
alternative types of programmed cell death mediated by other proteases, such 
as calpains and cathepsins 41. However, specific inhibitors of the lysosomal 
proteases cathepsin B or D (Figure 1E) or of the protease calpain (data not 
shown) also failed to protect against KF-induced cytotoxicity. In line with a 
previous study in prostate and breast cancer cells 42, our data indicate that KF 
induces a necrosis-like cell death process. 
We provide several lines of evidence that point to ErbB3 as a major 
determinant of KF action. First, the inverse correlation between ErbB3 
expression and KF IC50 values within the panel of human tumor cell lines 
suggests ErbB3 as a marker for KF-sensitivity. Second, exposure to KF results in 
downregulation of ErbB3 protein expression, which was observed in cells 
exposed for a short time (4 h) to KF as well as in KF-resistant cells that were 
selected over a longer period of time in KF-containing medium. Third, KF 
treatment induced downregulation of ErbB3 primarily in the detached, dying 
cell fraction, but not in the attached cell fraction. Finally, H460 cells ectopically 
expressing ErbB3 were more sensitive for KF treatment than cells transfected 
with an empty vector. Together, this indicates that downregulation of ErbB3 in 
cells that depend on ErbB3 for their survival contributes to the cytotoxicity of KF. 
Interestingly, H460 cells transfected with full length ErbB3 cDNA expressed a 
smaller, 125 kD protein. Others have demonstrated that ErbB3 exists in several 
isoforms of different sizes, including the truncated extracellular domain of about 




the cytoplasm 43,44. However, the 125 kD protein that we also observed has not 
been described. Under-glycosylation or proteolytic cleavage of the full-length 
protein may potentially account for the reduced ErbB3 protein size in H460 cells. 
In turn, low expression levels of full-length, functional ErbB3 is one of the factors 
that may account for the limited effect of ErbB3 transfection. Several other 
factors, however, might contribute to the relatively small differences between 
the IC50 values of ErbB3- and empty vector-transfected H460 cells. On one hand, 
since ErbB3 lacks intrinsic kinase activity, functional ErbB3 also requires the 
expression of other ErbB receptors, which is poor in H460 cells (see Figure 2). On 
the other hand, the use of pooled transfectants may have masked larger 
cytotoxic effects induced by KF, as a subpopulation of the cells may express only 
small amounts of ErbB3. 
KF-mediated depletion of ErbB3 was accompanied by a rapid decrease in Akt 
phosphorylation and inhibition of downstream signaling, an effect that was only 
observed in sensitive, ErbB3-expressing cells. This finding, together with our 
observation that blockage ofthe PI3K/Akt pathway with the PI3K inhibitor 
LY294002 did not affect ErbB3 expression (data not shown), suggests that 
inhibition of Akt signaling reflects KF-mediated ErbB3 depletion. This is also 
consistent with the notion that functional ErbB3 is required for Akt activity in 
cells that depend on ErbB2 and ErbB3 for their growth and survival, such as 
SKBR3 cells 45.  
Our data indicate that KF-mediated inhibition of the ErbB3-Akt pathway 
contributes to KF cytotoxicity, as cells transfected with a constitutively active 
mutant of Akt were largely protected against KF-cytotoxicity. Moreover, the KF-
resistant cell line HT29/KF showed increased basal Akt phosphorylation 
compared to its parental, KF-sensitive cell line HT29, which was not decreased 
after KF exposure. However, no KF-mediated inhibition of Akt phosphorylation 
was observed in ErbB3-transfected H460 cells (data not shown). Akt activity is 
partially uncoupled from growth factor receptor activity in H460 cells (Janmaat 
et al, 2003), providing a possible explanation for the observation that ErbB3 
depletion does not affect Akt activity in these cells. Akt is a major downstream 
target of receptor tyrosine kinases that signal via PI3K 46, and possesses pro-
survival and anti-apoptotic activities 47. Although the role of Akt in apoptosis 
suppression is well established 48, little is known about the involvement of Akt in 
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necrosis-like cell death. Akt inactivation has been observed in multiple types of 
caspase-independent cell death induced by agents such as N-methyl-D-
aspartate, nitric oxide, hydrogen peroxidase, and ansamycin antibiotics 49,50. 
Similar to our results with KF, the introduction of a constitutively active mutant 
of Akt suppressed N-methyl-D-aspartate toxicity 51. However, the exact 
underlying mechanism remains to be investigated. 
The demonstration that ErbB3 expression levels correlated with KF sensitivity 
may explain the reported preferential effect of KF on tumor versus normal cells 
52,53, as ErbB3 is commonly overexpressed in tumors 54. However, the NSCLC cell 
line A549, with low ErbB3 levels, was highly sensitive for KF, suggesting that 
ErbB3 expression levels alone are not predictive of KF sensitivity in all cases. 
Although A549 cells show low ErbB3 expression, their survival is dependent on 
ErbB3 expression, as selective ErbB3 depletion using RNA interference has been 
shown to induce cell death in this cell line 55.  
In contrast to an earlier observation of KF-mediated inhibition of EGFR and 
ErbB2 4,56, we did not detect any significant, direct effect of KF treatment on 
EGFR or ErbB2 expression (Figure 3) or phosphorylation in A431 or SKBR3 cells, 
respectively (data not shown). However, the observation that besides ErbB3 
other ErbB receptors were also downregulated to some extent during the 
selection process of the KF-resistant HT29 subline, might reflect an indirect 
effect of KF on the expression of other ErbB receptors, and suggests a potential 
role of multiple members of the ErbB family in KF-sensitivity.  
The mechanism by which ErbB3 is downregulated by KF remains to be 
clarified. KF-induced downregulation of ErbB3 is not due to inhibited synthesis 
of the receptor, as treatment of SKBR3 cells with the protein synthesis inhibitor 
cyclohexamide (50 µM) for 4h did not affect ErbB3 expression levels, while 
expression of p27kip1 was downregulated in these cells (data not shown). These 
data thus indicate that ErbB3 downregulation is due to degradation rather than 
inhibition of protein synthesis. ErbB3 protein can be ubiquitinated by the 
ubiquitin ligase Nrpd1 and subsequently degraded by proteasomes 57,58. 
However, KF-induced ErbB3-degradation was not proteasome-mediated, as co-
treatment of cells with the proteasome inhibitors MG-132 or PS-341 failed to 
protect from KF-induced ErbB3 depletion (data not shown). Alternatively, KF 




degradation, similar to EGF-mediated internalization of the EGFR 59. However, it 
remains to be elucidated if and how KF binds ErbB3.  
The data presented here may have important clinical relevance. We 
demonstrate that KF is active in vitro against cells derived from various tumor 
types, including breast, colon, NSCLC, and hepatic carcinomas at clinically 
relevant concentrations. Moreover, our finding that ErbB3 expression levels 
correlate with sensitivity of cell lines to KF suggests ErbB3 as a marker for KF 
sensitivity. Furthermore, downregulation of ErbB3 expression or inhibition of 
Akt or downstream events, such as the cellular localization of p27kip1, could 
serve as surrogate markers for KF activity. Although these preclinical findings 
require confirmation in the clinic, our data further suggest that mutations 
leading to constitutive activation of the PI3K/Akt pathway, such as depletion of 
PTEN 60 or PIK3CA mutations 61 that have been identified in several tumor types, 
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The major aim of the investigation described in this thesis was to further 
understand the molecular mechanisms of ErbB-targeting anti-tumour agents, and to 
identify biological markers that predict the outcome of cancer patients treated with 
such agents. 
 
To address these issues, we started to investigate the molecular mechanism of 
action of the EGFR-TKI gefitinib and the EGFR antagonistic antibody C225. Despite the 
promising activity seen in several NSCLC patients in early clinical trials with gefitinib 1-3, 
we observed only small anti-proliferative effects of anti-EGFR agents in NSCLC cell lines 
in vitro. On the contrary, the growth of the EGFR-overexpressing cell line A431 was 
effectively inhibited due to an arrest of cells in the G1-phase of the cell cycle (Chapter 2). 
Correspondingly, the survival of NSCLC cells remained unaffected upon treatment with 
EGFR inhibitors, whereas apoptotic cell death was induced in A431 cells. As may have 
been expected (Figure 1), we demonstrated that apoptosis induced by EGFR inhibitors 
involved a mitochondrial step (Chapter 2). However, apoptotic cell death induced by 
EGFR inhibitors has only been observed in some tumour cells 4-10, indicating that the 
induction of apoptosis is not a general mechanism of action of this type of agents. 
 
Figure 1.  Interference of the EGFR pathway on apoptosis. Apoptosis can be induced via two distinct 
pathways. Activation of death receptors by their ligands results in apoptotic cell death via subsequent 
activation of FADD, Caspase 8, and downstream effector caspases, such as Caspase 3. On the other hand, 
DNA damage induced by for instance chemotherapy may result in the release of Cytochrome C from 
mitochondria, which together with the co-factor Apaf1 activates Caspase 9. Activated Caspase 9 induces 
downstream activation of effector caspases, resulting in the execution of apoptosis. Activation of the 
EGFR pathway has an inhibitory effect on Caspase 9 mediated apoptosis by activating the PI3K-Akt 
pathway, which results in the retention of Cytochrome C in mitochondria mediated by anti-apoptotic 





























Next, we sought to resolve which factors determine anti-EGFR sensitivity and resistance. 
We hypothesized that tumour cells that strongly depend on the EGFR pathway for their 
growth and survival would be most sensitive to EGFR inhibitors. Initially, we and others 
found that EGFR expression levels do not directly correlate with sensitivity to EGFR 
inhibitors 5,11,12. However, the discovery of EGFR kinase domain mutations provided an 
entirely new perspective in the research field. The finding that the presence of these 
mutations strongly correlates with gefitinib-sensitivity 13-15 also lead to the novel 
appreciation of the importance of EGFR expression levels, particularly due to gene 
amplification, as a marker of anti-EGFR activity in EGFR wild-type cell lines and tumours 
16-18 (Chapter 3 and 4). For instance, we showed that high EGFR protein expression in 
esophageal tumours, in which no mutations in the EGFR tyrosine kinase domain were 
found or reported, predicts for increased sensitivity to gefitinib treatment (Chapter 4). 
Together, these data suggest that EGFR expression levels may be related to EGFR-TKI 
sensitivity of wild type EGFR tumours, including wild type EGFR NSCLCs. However, 
discrepancy exists in the literature about the role of EGFR (over)expression as marker of 
anti-EGFR therapy or as prognostic factor in some tumour types, in large part because 
of the wide variety in detection methods and cut-offs used to define overexpression 
(reviewed in 19). In this respect, analysis of gene amplification would be a reproducible 
and objective method. However, high EGFR expression does not appear to be the result 
of gene amplification in all cases 17 (Chapter 4). Thus, in order to use EGFR as marker for 
anti-EGFR therapy or as prognostic factor it will be important to introduce a widely 
accepted standard test to evaluate EGFR protein expression levels in tissues, similar to 
the standardized investigation of Her2/neu expression in breast cancer (DAKO 
HercepTestTM) to identify candidates for treatment with trastuzumab 20. 
The finding that EGFR kinase domain mutations in NSCLCs are associated with 
EGFR-TKI sensitivity is definitively a major breakthrough 13-15. Indeed, many 
retrospective, follow-up studies have confirmed this association in NSCLCs, including a 
study in our group 21 (M.I. Gallegos-Ruiz et al., unpublished data). However, 
fundamental differences appear to exist between gefitinib and erlotinib with respect to 
EGFR mutations. While 46-80% of NSCLC patients with EGFR mutations respond to 
gefitinib monotherapy 16,17, only about 15% of patients with EGFR mutations had a 
response upon erlotinib treatment 18,22. Based on these data, the importance of EGFR 




Figure 2.  Correlation between the mutational status of EGFR and k-ras and sensitivity for gefitinib 
or cetuximab in a panel of NSCLC cell lines and A431 vulval carinoma cells. Cell growth was measured 
in MTT assays after 72 h treament. Note that the cell line with an EGFR mutation is sensitive for treatment 
with gefitinib but not cetuximab. Cell lines with k-ras mutations are less sensitive to treatment with 
gefitinib or cetuximab. 
 
evaluated in prospective studies with gefitinib and further retrospective studies with 
erlotinib. 
In contrast to EGFR-TKIs, recent data, including from our lab, suggest that the EGFR-
specific mAb cetuximab does not effectively the viability of EGFR-mutated tumour cells 
23,24 (Figure 2). Apparently, extracellular antibody binding of EGFR does not affect the 
proliferative and pro-survival potential of the mutated EGFR. 
In addition to EGFR expression, amplification, and mutations, the impact of Erk and 
Akt phosphorylation status has been extensively studied. We were among the first to 
show that EGFR-independent activity of the Erk and Akt pathways confers resistance of 
tumour cells to anti-EGFR agents in vitro (Chapter 2). EGFR-independent activity of these 
kinase pathways can be mediated by multiple factors, including PTEN depletion and k-
ras mutations, which have been directly associated with gefitinib resistance in vitro and 
in patients 25-27 (Chapter 3 and 4). Positive immunohistochemical staining of NSCLC 
tissue for phosphorylated Akt but not phosphorylated Erk has been associated with 
sensitivity of patients to gefitinib by Cappuzzo et al 28. However, we have not observed 
such correlation in the study investigating gefitinib in esophageal cancer (Chapter 4). 
These differences may reflect dissimilarities between the tumour types. On the other 
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hand, as with EGFR stainings, the discrepancy may be due to differences in scoring 
methods. In fact, Cappuzzo et al used a method for scoring phosphorylated Akt staining 
that was based on the presence of nuclear staining 28, whereas we used a method that 
was based on staining incidence and intensity. A complicating factor is that we were 
not able not score a substantial amount of esophageal tissues for phosphorylated Akt 
due to staining of normal tissue surrounding the tumour cells in (Chapter 4). In most 
immunohistochemical studies, including ours, only one Akt phosphorylation site (S473) 
has been evaluated. However, a recent report suggests that the evaluation of the two 
phosphorylation sites (T308 and S473) that are required for full Akt activation improves 
the prognostic significance of Akt activation 29. 
In addition to the primary resistance related to the presence of k-ras mutations or 
EGFR-independent activity of Erk or Akt pathways, acquired resistance to erlotinib or 
gefitinib has been associated with a secondary point mutation in the EGFR tyrosine 
kinase domain 30,31. In addition to acquired resistance, the T790M mutation has been 
found to be present at the time of diagnosis in several studies 32,33. The finding that 
treatment with several ErbB-TKIs can overcome resistance associated with a secondary 
mutation 34,35 suggests that second-generation EGFR-TKIs can be of importance in the 
treatment of NSCLC. Strikingly, the identified second-generation EGFR-TKIs were all 
irreversible inhibitors of EGFR in contrast to gefitinib and erlotinib, suggesting 
improved efficacy of irreversible TKIs against the resistant EGFR mutant in comparison 
with reversible TKIs. 
Altogether, the above-described data are in line with our initial hypothesis that cells 
that strongly depend on EGFR signalling for their growth and survival are sensitive to 
EGFR antagonists. Targeting kinases on which cancer cells strongly depend for their 
proliferation and survival, a phenomenon also referred to as kinase addiction 36, has 
been proven to be a successful anti-cancer strategy in several cases. In addition to 
successful treatment of EGFR-dependent lung tumours with EGFR tyrosine kinase 
inhibitors, patients with chronic myeloid leukaemia (CML) aberrantly expressing the 
BCR-ABL fusion protein can be successfully treated with the tyrosine kinase inhibitor 
imatinib (GleevecTM) 37. Other examples of successful treatment of kinase-addicted 
tumours are therapy of ErbB2-overexpressing breast cancer patients with the anti-
ErbB2 antibody trastuzumab (HerceptinTM) 38, and treatment of patients with gastro-
intestinal stromal tumours (GIST) with activating c-kit or PDGFR mutations with the 
multi-targeting tyrosine kinase inhibitor imatinib 39,40. Moreover, the similarity between 
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imatinib and EGFR-TKIs extents to the ultimate development of acquired resistance that 
have been associated with secondary mutations in target genes in both cases 30,31,41,42. 
 
Besides the molecular markers of sensitivity to EGFR-TKIs that have been described 
above, several clinical parameters have been put forward that correlate with EGFR-TKI 
sensitivity in NSCLC patients, which include female gender, Asian ethnicity, non-
smoking history, and adenocarinoma histology 18,43-45. In contrast to NSCLCs, we found 
that SCC histology is a predictive factor for beneficial outcome of gefitinib-treated 
esophageal cancer patients (Chapter 4). The higher incidence of EGFR mutations in lung 
adenocarcinomas compared to SCCs is likely to be the reason why lung cancer patients 
with adenocarcinoma histology respond better to gefitinib. In contrast to NSCLCs, no 
EGFR mutations are present in esophageal carcinomas. Esophageal SCC patients may 
have a better outcome than esophageal adenocarcinoma patients due to a higher rate 
of EGFR overexpression in SCCs (Chapter 4). 
An issue that needs to be addressed includes the question if broader selectivity of 
EGFR-TKIs impacts the anti-tumor efficacy. For instance, objective and minor responses 
were achieved with the EGFR/ErbB2 inhibitor GW-572016 in patients pretreated with 
gefitinib or trastuzumab, indicating that a broader specificity may be more effective in 
some cases. However, a major drawback is the higher toxicity observed in patients 
treated with agents targeting multiple ErbB receptors, possibly due to nonspecific side 
effects. An alternative may be treatment with combinations of highly specific agents, 
such as combined treatment with gefitinib and trastuzumab, which has been 
successfully assessed in patients with advanced breast cancer 46. Several reports 
demonstrated that combination treatment with gefitinib and cetuximab may be an 
effective strategy 47,48. The recent observation that two patients responded to gefitinib 
after failure of several chemotherapy regimens and cetuximab 49 favors the view that 
monoclonal antibodies and TKIs have different mechanisms of action and might be 
effectively combined. On the other hand, we demonstrated in Chapter 3 that 
combinations of gefitinib and specific inhibitors of the Ras/Erk and PI3K/Akt pathways 
induced enhanced cytotoxicity in NSCLC cells in vitro. These data were obtained in cell 
lines with EGFR-independent activity of the Ras/Erk and PI3K/Akt pathways, 
respectively. The results described above are examples of effective cell-specific 
treatment combinations, resulting from molecular characterization of specific cellular 
defects. When extrapolated to the treatment of patients, one may aim to achieve 
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patient-specific treatment with cocktails of targeted agents in the future, in contrast to 
the current tumor-type guided treatment with non-specific cytotoxic agents. 
 
In addition to rationally developed selective EGFR inhibitors, we have investigated 
the molecular mechanism of action of the marine-derived depsi-peptide Kahalalide F. 
KF has specific and potent preclinical anti-tumour activity in vitro and in vivo 50-54. KF 
rapidly induces disruption of membranes, particularly lysosomal membranes, followed 
by caspase-independent cell death 55,56 (Chapter 5). Initially, KF has been described to 
inhibit the activation of EGFR and ErbB2 and to downregulate TGFα 51,57. In contrast to 
EGFR or ErbB2, we have provided several lines of evidence that point to ErbB3 as a 
major determinant of KF action. First, we have found an inverse correlation between 
ErbB3 expression and KF sensitivity within a panel of human tumour cell lines. Second, 
exposure to KF results in down-regulation of ErbB3 protein expression, which was 
observed in cells exposed for a short time (4 h) to KF and in KF-resistant cells that were 
selected over a longer period of time in KF-containing medium. Third, KF treatment 
induced down-regulation of ErbB3 primarily in cells that were detached from the 
bottom of the tissue culture plastic and were presumed to be dead, but not in cells that 
remained attached and were viable. Finally, the most resistant cell line in our panel that 
ectopically expressed ErbB3 became more sensitive for KF treatment than cells 
transfected with an empty control vector. Together, this indicates that down-regulation 
of ErbB3 in cells that depend on ErbB3 for their survival contributes to the cytotoxicity 
of KF.  
KF-mediated depletion of ErbB3 was accompanied by a rapid decrease in Akt 
phosphorylation and inhibition of downstream signalling, an effect that was only 
observed in sensitive, ErbB3-expressing cells. This suggests that inhibition of Akt 
signalling reflects KF-mediated ErbB3 depletion, in line with other reports showing the 
requirement of ErbB3 for PI3K-Akt signalling 58. Conversely, ectopic expression of a 
constitutively active Akt mutant in a cell line sensitive to KF largely protected against 
KF-induced cytotoxicity. In summary, our results identify ErbB3 and the downstream 
PI3K-Akt pathway as important determinants of the cytotoxic activity of KF in vitro 
(Chapter 5). 
In line with previous data, Sewell et al recently showed that the pattern of cell 
permeability induced by KF is similar to maitotoxin, another small cytotoxic peptide 59. 
However, the authors suggested specific interactions with membranes or proteins 
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because of the differential effects of KF on the cell membrane in different hepatoma cell 
lines 59. Our data clearly point to ErbB3 as a candidate for such specific interaction with 
KF. In contrast to the anti-tumour activity of EGFR inhibitors, KF-induced cytotoxicity 
cannot just be explained by targeting a single receptor. Nevertheless, our data may 
have impact on selecting patients that could benefit from treatment with KF. In 
addition to this, our data initiated combinations studies of KF and ErbB inhibitors that 
are currently being evaluated in preclinical studies (J. Jimeno, personal 
communication).   
 
In conclusion, ErbB targeting agents have shown anti-tumor activity against many 
types of cancer, including NSCLC. Although much progress has been made in recent 
years, the data of (prospective) clinical trials with accompanying detailed molecular 
tumor profile is required to further identify the subpopulation of patients that benefit 
from this type of therapy. Moreover, more detailed research is needed to improve the 
efficacy of ErbB targeting agents in combination with chemotherapy, radiotherapy, or 
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 Kanker is een groot probleem in de westerse wereld: in Nederland is het op dit 
moment de tweede doodsoorzaak na hart en vaatziekten, maar de verwachting is dat 
het  binnen enkele jaren de belangrijkste doodsoorzaak zal worden. 
 Kanker ontstaat doordat normale cellen in het lichaam ongecontroleerd delen 
en overleven. In normale weefsels is er een balans tussen cellen die delen en cellen die 
gecontroleerd doodgaan. De proliferatie en overleving van tumorcellen is daarentegen 
een ongecontroleerd proces, dat leidt tot een wildgroei van cellen en uiteindelijk het 
ontstaan van kwaadaardige gezwellen: kanker. 
 De deling en overleving van normale cellen uit het menselijke lichaam is een 
nauwgezet en gereguleerd proces, dat wordt geactiveerd door factoren uit de directe 
omgeving van cellen, zoals hormonen en groeifactoren. Groeifactoren en hormonen 
kunnen cellen aanzetten tot groei, doordat ze aan receptoren (een soort antennes) 
binden, die voorkomen op het cel-membraan aan de buitenkant van de cel. Hiermee 
geven ze een signaal af die de receptoren op hun beurt doorgeven naar de binnenkant 
van de cel. Hier vindt achtereenvolgens een reeks van chemische reacties plaats 
(signaal transductie), die uiteindelijk leidt tot activiteit van het DNA in de kern van de 
cel en  deling en overleving van de cel. Aan de andere kant zullen cellen niet overleven 
als ze beschadigd zijn, een gebrek aan groeifactoren hebben, of een specifiek signaal 
krijgen en een proces van gecontroleerde celdood (apoptose) in gang zetten. 
 Opeenhoping van DNA mutaties of veranderingen in de expressie van genen die 
de groei en overleving van cellen controleren dragen bij aan het ontstaan van kanker. 
Het is al enige tijd bekend dat ongecontroleerde en verhoogde activiteit van de 
epidermale groeifactor receptor (EGFR) en gerelateerde receptoren (de ErbB 
receptoren) belangrijke factoren zijn die bijdragen aan de ontwikkeling van 
verschillende vormen van epidermale tumoren. Hieronder vallen tumoren van de long, 
borst, hersenen, en hoofd- en halstumoren. Als gevolg van dit inzicht zijn verschillende 
middelen ontwikkeld die specifiek aangrijpen op de EGFR en de activiteit van de EGFR 
remmen. Kleine moleculen die specifiek de enzymatische activiteit van de EGFR 
remmen (tyrosinekinase remmers), zoals gefitinib (Iressa)  en erlotinib (Tarceva), en 
EGFR-specifieke, monoklonale antistoffen, zoals cetuximab (Erbitux), worden 
momenteel getest in klinische studies en/of zijn al geregistreerd als antikankermiddel. 
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 Een veelgebruikte therapie tegen kanker is chemotherapie, dat de sneldelende 
tumorcellen doodt. Helaas worden ook normale delende cellen door chemotherpie 
gedood, wat zorgt voor een aantal vervelende bijwerkingen (zoals bloedarmoede, 
vermoeidheid, haarverlies en misselijkheid). Een groot voordeel van EGFR remmers ten 
opzichte van klassieke chemotherapie, is dat deze middelen veel specifieker op 
tumorcellen aangrijpen en daardoor minder en mildere bijwerkingen geven. Een 
nadeel is dat EGFR remmers maar in een klein percentage van de patiënten werken, 
omdat EGFR maar in een gedeelte van de patiënten verantwoordelijk is voor het 
ontstaan van hun ziekte. 
 In dit proefschrift hebben we nader onderzoek gedaan naar de 
werkingsmechanismen van EGFR remmers. Het doel was om moleculaire 
eigenschappen te identificeren waaruit kan worden afgeleid of tumor(cell)en gevoelig 
dan wel resistent zijn voor behandeling met EGFR remmers.  
 
 In hoofdstuk 1 wordt een algemene inleiding gegeven over de EGFR signaal 
transductie route en de rol hiervan tijdens de embryonale ontwikkeling en in kanker. 
Ook wordt er een overzicht gegeven van de status van EGFR remmers in preklinische en 
klinische studies. 
 In hoofdstuk 2 onderzoeken we de moleculaire en cellulaire werkings-
mechanismen van EGFR remmers in longkankercellen. Na aanleiding van 
veelbelovende resultaten met de EGFR remmer gefitinib in longkankerpatiënten, waren 
we geïnteresseerd in de werkingsmechanismen van gefitinib in longkankercellen en 
hebben dit vergeleken met het EGFR-specifieke antilichaam cetuximab. In tegenstelling 
tot de resultaten in de kliniek, vonden we dat alle geteste cellijnen ongevoelig waren 
voor behandeling met EGFR remmers. Deze resistente cellijnen bleken  hun 
intracellulaire signaal transductie onafhankelijk van EGFR te activeren. Deze resultaten 
suggereren dus dat EGFR-onafhankelijke activatie van intracellulaire signaaltransductie 
geassocieerd is met resistentie tegen EGFR remmers. 
 In hoofdstuk 3 vonden we dat gecombineerde behandeling van gefitinib met 
specifieke remmers van intracellulaire signaal transductie leidde tot een verminderde 
celdeling en/of verhoogde celdood van longkankercellen die resistent zijn voor EGFR 
remmers. Verder vonden we in dit hoofdstuk dat er een aantal longkanker cellijnen ook 
gevoelig zijn voor behandeling met gefitinib. Deze gevoeligheid bleek te zijn 
geassocieerd met hoge expressie van EGFR of mutaties in het DNA dat codeert voor de 
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receptor (EGFR gen). Omgekeerd bleken mutaties die voorkomen in het DNA van het 
intracellulaire signaaltransductie eiwit k-Ras geassocieerd te zijn met resistentie tegen 
EGFR remmers. 
 Hoofdstuk 4 beschrijft de resultaten van een klinische studie van gefitinib in 
eerder behandelde slokdarmkankerpatiënten in een vergevorderd stadium; dit is een 
groep patiënten die zeer moeilijk te behandelen is. Hoewel er van de 36 beoordeelde 
patiënten maar één patiënt (2,8 %) een remissie had na behandeling met gefitinib 
(d.w.z. een tumor die kleiner wordt),  had een relatief groot aantal van 27,8 % minimaal 
een stabiele ziekte tijdens behandeling met gefitinib (d.w.z. een tumor die niet groeit). 
Vervolgens hebben we van deze groep van patiënten het tumorweefsel bestudeerd 
voor een aantal biologische kenmerken. Er werden in deze tumoren geen mutaties in 
het EGFR gen, maar het resultaat van patiënten met een hoge expressie van het EGFR 
eiwit was significant beter. Mutatie in het k-ras gen bleken juist voor te komen in 
patiënten met een voortgaande ziekte tijdens de behandeling met gefitinib. Ook 
bleken vrouwen en patiënten met een plaveicelcelcarcinoom histologie een significant 
beter resultaat te hebben. 
 In hoofdstuk 5 onderzoeken we de moleculaire en cellulaire werkings-
mechanismen van het experimentele antikanker middel kahalalide f (KF). KF bleek op 
een erg krachtige manier kankercellen te kunnen doden. In tegenstelling tot eerdere 
publicaties, waarin werd gesuggereerd dat KF de activiteit van EGFR en/of de 
gerelateerde ErbB2 receptor zou remmen, vonden wij dat KF de expressie van een 
ander EGFR familielid verlaagt: de ErbB3 receptor. Hierdoor werd ook de intracellulaire 
signaaltransductie via PI3K-Akt geremd en daarmee de signalen die cellen nodig 
hebben om te overleven. 
 Tenslotte worden de resultaten die beschreven zijn in dit proefschrift en hun 
implicaties in de kliniek besproken in hoofdstuk 6. Het lijkt nu duidelijk te worden dat 
EGFR remmers effectief zijn bij bepaalde vormen van kanker, met name longkanker. 
Recent onderzoek richt zich op het bepalen van de subpopulatie van patiënten die 
voordeel heeft bij behandeling met EGFR remmers. Tumorcellen met EGFR mutaties, of 
hoge EGFR expressie zijn gevoelig voor EGFR tyrosinekinase remmers. EGFR-
onafhankelijke activiteit van intracellulaire signaaltransductie door ondere andere k-ras 
mutaties is juist geassocieerd met resistentie tegen EGFR remmers.  
De verwachting is dat deze ontwikkeling er uiteindelijk toe zal leiden dat de 
behandeling van kankerpatiënten steeds persoonlijker zal worden. 
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List of Abbreviations 
 
AD adenocarcinoma 
CDDP cisplatin  
cfu colony forming units  
DNA deoxyribonucleic acid 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor  
Erk extracellular signal-regulated kinase 
FACS fluorescent activated cell sorter 
FCS fetal calf serum  
FITC fluorescein isothiocyanate  
GSK-3β glycogen synthase kinase 3β 
kDa kilo Dalton  
KF kahalalide f  
mAb monoclonal antibody  
MAPK mitogen activated protein kinase 
MEK mitogen-activated protein kinase kinase  
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
NSCLC non-small cell lung cancer 
PARP poly (ADP-ribose) polymerase  
PBS phosphate buffered saline  
PCR polymarase chain reaction  
PI propidium iodide 
PI3K phosphatidylinositol 3-kinase  
PKB protein kinase B 
PS phosphatidyl serine 
SCC squamous cell carcinoma 
SD standard deviation  
TGFα transforming growth factor α 
TKI tyrosine kinase inhibitor 
Wt wild type 
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getiteld: ‘Targeting ErbB receptors as anticancer therapy: Factors of sensitivity and 
resistance’. 
 Tijdens de afronding van dit proefschrift is hij begonnen aan een postdoc 
project bij de afdeling Geneeskundige Oncologie aan het VU Medisch Centrum (VUMC) 
in de groep van Prof. E. Boven. In dit project bestudeert hij de rol van PDGF 
signaaltransductie in eierstokkanker. 
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